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1 Introduction 
 “Malaria remains a major killer of children, taking the life of a child every two 
minutes.” (World Health Organization 2016) 
 
A considerable decline of incidence and mortality of malaria was achieved during the 
past years. Still, malaria remains one of the major health issues worldwide: in 2015, an 
estimated 212 million infections and 429 000 deaths, mostly of children aged 5 years or 
younger, were registered. The burden of malaria is disproportionately high in sub-
Saharan Africa: 92 % of deaths from malaria are reported in this region. Burkina Faso 
belongs to the high transmission countries and is one of the poorest countries 
worldwide, which combines two major factors facilitating malaria (World Health 
Organization 2016). 
Developing and evaluating new antimalarial drugs belongs to the most important 
instruments of fighting malaria. Genotyping of secondary infections after treatment is 
an essential tool to monitor the efficacy of antimalarial agents with high accuracy. 
1.1 Malaria parasite 
1.1.1 Discovery and classification  
Malaria (deriving from the Italian mal’aria meaning “bad air”) is caused by a protozoan 
parasite of the genus Plasmodium. Febrile diseases have been linked to swampy areas 
for thousands of years. However, the malaria parasite has been recognized as its cause 
only towards the end of the 19th century.  
The first person to describe the parasite in human blood was Laveran in 1880. What 
followed in the next twenty years was research on the parasite’s life cycle and its 
transmission: Ross was the first person to publish the full malaria life cycle in 1898 
after having conducted several studies on avian Malaria and the Italian scientists 
Bignami and Grassi proved that the parasites are transmitted by inoculation of a female 
Anopheles mosquito (Cox 2010)(Ross 1898).  
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The life cycle of Plasmodium takes place both in the female Anopheles mosquito and in 
a human host. The Anopheles mosquito serves Plasmodium as a vector into the human 
body: by feeding on humans, it might inject one or several species of Plasmodium into 
the capillary system.  
The human pathogenic species are  
• Plasmodium falciparum 
• Plasmodium ovale 
• Plasmodium vivax 
• Plasmodium malariae 
• Plasmodium knowlesi 
 
Malaria in humans can be caused by all of the listed Plasmodium spp. but the disease 
shows different characteristics depending on the infecting species. Whereas 
Plasmodium ovale and Plasmodium vivax are responsible for 48-hour fever attacks 
(Malaria tertiana), Plasmodium malariae evokes fever attacks every 72 hours (Malaria 
quartana). Plasmodium vivax and Plasmodium ovale are the only Plasmodium spp. to 
generate dormant liver stages, termed hypnozoites (Campo et al. 2015). These dormant 
liver stages induce relapses for up to a decade (Ashley & White 2014). 
Plasmodium knowlesi has a shared reservoir between Southeast Asian macaques and 
humans. Up to 1971, only four authenticated cases of Plasmodium knowlesi malaria had 
been reported, but reports have been augmenting since 2004. Usually, Plasmodium 
knowlesi malaria results in uncomplicated malaria but it causes severe malaria in 10 % 
and is fatal in 1 – 2 % of cases (Millar & Cox-Singh 2015). 
Malaria tropica on the other hand is characterized by irregular fever spikes and is 
caused by Plasmodium falciparum (P. falciparum). It can lead to severe malaria and it 
is responsible for 99 % of all malaria deaths (World Health Organization 2016). Below, 
I will focus on P. falciparum malaria due to its importance and high prevalence of 95 % 
of all malaria infections in Burkina Faso (Samadoulougou et al. 2014). 
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1.1.2 Life cycle of Plasmodium falciparum 
Asexual stage in a human 
The asexual stage of the protozoan’s life cycle consists of a clinically silent pre-
erythrocytic phase and a pathogenic intra-erythrocytic cycle: the pre-erythrocytic phase 
begins when the Anopheles mosquito inoculates a human with sporozoites. The 
sporozoites follow the bloodstream towards the liver and invade hepatocytes. They 
multiply as hepatic schizonts and produce several thousand merozoites, which are then 
released into the blood (Siciliano & Alano 2015). A single sporozoite can produce up to 
30 000 merozoites (White et al. 2015). Merozoites invade red blood cells (RBC) by 
ligand-receptor-interactions and then develop from ring-stages to trophozoites to 
erythrocytic schizonts, which eventually release about 20 merozoites (Miller et al. 
2002). These progenies re-enter the intra-erythrocytic cycle. The haploid set of 14 
chromosomes is replicated by mitosis, whereas cell division (cytokinesis) occurs by a 
non-canonical process, termed schizogony. Few merozoites transform into sexual 
stages, the gametocytes. 
Sexual stage in the female Anopheles mosquito 
These female and male gametocytes can now be ingested by an Anopheles mosquito and 
consequently enable transmission. By feeding on an infected human being, the female 
Anopheles incorporates female and male gametocytes, which fuse and become a motile 
diploid zygote, the ookinete. This is the scene of meiotic replication and therefore 
exchange of genetic information between desoxyribonucleic acid (DNA) from the 
female and male gametocyte. The ookinete penetrates the Anopheles’ gut wall and then 
transforms into an oocyst, in which thousands of sporozoites are produced. The oocyst 
bursts and releases the sporozoites, which migrate towards the anopheline salivatory 
glands (Siciliano & Alano 2015). With the next blood meal, the sporozoites are injected 
into the human host and a new asexual life cycle of P. falciparum begins.  
Figure (Fig.) 1 depicts the life cycle of P. falciparum. 
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Figure 1: Life cycle of P. falciparum. Asexual replication: (1) Sporozoites are inoculated by an 
Anopheles mosquito into a human host. The sporozoites travel in capillaries and vessels into the 
liver (2), where they penetrate hepatocytes and become liver-schizonts. The liver-schizonts burst 
and release merozoites (3), which penetrate red blood cells (4). In the red blood cells, the 
merozoites develop from ring stages (5) over trophozoites into blood-schizonts (6), which burst 
and release merozoites (7). Most merozoites enter a new red blood cell and repeat the intra-
erythrocytic cycle. Few merozoites develop into female and male gametocytes (8), which are 
ingested by a female Anopheles during a blood meal. Transmission of P. falciparum is hereby 
enabled. Sexual stage: The microgametocyte and microgametocyte fuse into a zygote (9) and 
travel to the Anopheles’ mid-gut. The zygote develops towards an ookinete (10) and further into 
an oocyst (11), which produces sporozoites. The oocyst bursts (12) and sporozoites travel 
towards the Anopheles’ salivary gland, from where they are inoculated into a human host with 
the next blood meal. 
1.2 Prevention of malaria 
1.2.1 Insecticide treated bed nets and indoor residual spraying 
Insecticide treated bed nets (ITNs) and indoor residual spraying (IRS) with insecticides 
are fundamental methods of malaria control. Since Anopheles mosquitoes are mostly 
active during the night, sleeping underneath a bed net ensures protection against malaria 
in these hours. 53 % of the population at risk in sub-Saharan Africa slept underneath an 
ITN in 2015, and only 42 % of households held enough ITNs for each family member. 
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Resistance to pyrethroids, the insecticide used in ITNs, is increasing but studies show 
that ITNs remain effective (World Health Organization 2016).  
1.2.2 Vaccines 
P. falciparum undergoes various morphological and cell biological changes during its 
development in the human host, which leads to a strong variation of antigenic display 
(Arama & Troye-Blomberg 2014). The development of a highly protective vaccine has 
not yet been achieved, but several approaches have been developed; these can be sub-
classified into transmission-blocking vaccines, pre-erythrocytic vaccines and blood-
stage vaccines.  A phase three trial of the pre-erythrocytic RTS,S/AS01 vaccine 
candidate showed insufficient protection of 55.8 % and 31.3 %, depending on age 
groups (The RTS,S Clinical Trials Partnership 2014)(The RTS,S Clinical Trials 
Partnership 2015). Newly published data from Tübingen show 100 % sterile protection 
in nine healthy, malaria-naive adults under chloroquine prophylaxis who were 
inoculated intravenously with chemoattenuated, non-irradiated P. falciparum sporozoite 
vaccine (Mordmüller et al. 2017). However, further clinical trials, including with 
heterologous challenge strains, have to be conducted. 
1.3 Treatment of malaria 
Antimalarial drugs have a long history. The first person to find an antimalarial 
chemotherapy was Paul Ehrlich in 1981, who found that methylene blue caused 
Plasmodium to vanish from the infected human’s blood (Guttmann & Ehrlich 1891). 
The alkaloid quinine was imported to Europe from South America in the 17th century as 
a component of the cinchona tree bark (Achan et al. 2011). It was isolated in 1820 and a 
century later, chloroquine and other synthetic antimalarial quinolones had been 
developed and were broadly distributed to treat malaria (Packard 2014). The spread of 
resistance to quinolines provoked further research on new antimalarial agents, which 
amongst others led to the isolation of artemisinin in the 1970s. Ever since the global 
introduction of artemisinin-based combination therapies (ACTs) starting around 15 
years ago, these drugs have had a major impact on the containment of malaria and are 
the current first-line therapy of uncomplicated malaria.  
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1.3.1 Treatment of uncomplicated P. falciparum malaria 
Uncomplicated P. falciparum malaria is defined by a positive blood smear and clinical 
malaria with no symptoms of severe malaria. Typical symptoms are high fever with 
ague, headache, fatigue and aching muscles. Uncomplicated malaria should be treated 
with an ACT (World Health Organization 2015). 
Artemisinin-based combination therapies  
Artemisia annua is a herb that has been used for centuries to cure fevers. The isolation 
of its antimalarial agent artemisinin in 1972 by Chinese scientists was an immense 
breakthrough in the fight against malaria (Klayman 1985) and was rewarded by the 
Nobel price for Youyou Tu in 2015. Artemisinin derivatives such as artemether, 
artesunate and dihydroartemisinin represent the antimalarials with the most potent anti-
parasitic activity against all Plasmodium species (Makanga & Krudsood 2009)(White 
2008). Once absorbed, all artemisinin derivatives convert into one active metabolite, 
dihydroartemisinin. 
To reduce the risk of treatment failure with short (3-day) regimens, artemisinin 
derivatives are administered not as monotherapies but as artemisinin-based combination 
therapies (ACT). ACTs have been recommended by the World Health Organization 
since 2001 as first-line treatment against uncomplicated P. falciparum malaria. 
Combining partner drugs is based on several rationales: the combination of two 
antimalarial agents endows this combination with two different modes of action. 
Furthermore, artemisinin derivatives would have to be administered for seven days due 
to their short elimination half-life. Seven-day dosage schemes show little compliance 
and combining the artemisinin derivative with a different antimalarial with a longer 
elimination half-life facilitates a three-day treatment. The short-acting artemisinin 
derivative is associated with a high parasite reduction ratio and kills off a majority of 
the parasite’s asexual stages effectively. As artemisinin derivatives have elimination 
half-lives of approximately one hour, they have to be combined with a more slowly 
eliminated partner drug, which shows a longer elimination half-life of more than one 
day to prevent recrudescent infections (Nosten & White 2007). 
The modes of action of artemisinin derivatives are not yet fully understood, but there 
are several hypotheses on the mechanisms such as interference of the artemisinin 
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derivatives with plasmodial sarcoplasmic / endoplasmic calcium ATPase, interference 
with mitochondrial electron transport, interference with parasite transport proteins and 
unfolded protein responses. It is known that artemisinin derivatives kill most intra-
erythrocytic parasite stages, including early ring stages, but have little effect on 
schizonts (ter Kuile et al. 1993).  
The following ACTs were examined in the present thesis and are therefore described 
more into detail: 
Artemether-lumefantrine 
Artemether-lumefantrine (AL) belongs to the most frequently prescribed ACTs to treat 
uncomplicated malaria. Lumefantrine, an aryl amino-alcohol, shows an elimination 
half-life of 3.2 days (Ezzet et al. 2000). Drawbacks of AL are a twice-daily dosing 
scheme and the necessity of administering AL with fats to ensure good absorption of 
lipophilic lumefantrine. 
Dihydroartemisinin-piperaquine 
Piperaquine is a bis-quinoline and even though its mode of action is not fully 
understood, it is assumed to have similar effects on Plasmodium as chloroquine. The 
terminal elimination half-life for piperaquine is of 20 - 22 days (Sigma-Tau 2011), 
leading to a considerably long PTP (Pfeil et al. 2014). This advantage has to be weighed 
against the long exposure of re-infecting parasites to low piperaquine concentrations, 
which potentially leads to faster selection of less sensitive strains. Furthermore, higher 
gametocytaemia after treatment with dihydroartemisinin-piperaquine (DP) compared to 
AL has been observed, which increases the risk of transmission (Bassat et al. 2009). 
Pyronaridine-artesunate 
Pyronaridine has an elimination half-life of 14 – 18 days (Shin Poong 2017h), and 
therefore also provides a long PTP. (Sagara et al. 2016) published data, which indicates 
that PA is safe and well tolerated in re-treatment with pyronaridine-artesunate (PA). 
This data, as well as the data for the thesis at hand, originates from the WANECAM 
clinical trial, which was conducted in Westafrica from 2012 to 2015. 
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1.3.2 Treatment of severe malaria 
Severe malaria is defined by presence of asexual P. falciparum parasitaemia and to 
name only the most important: coma, severe anemia and respiratory distress due to 
metabolic acidosis. If untreated, its case fatality rate is very high, and therefore should 
immediately be treated with intravenous or intramuscular artesunate for at least 24 
hours. This medication is to be followed by a complete treatment with an ACT (World 
Health Organization 2015). 
1.4 Monitoring antimalarial drug resistances 
Resistance to antimalarial drugs is defined as the capability of a parasite to survive or 
replicate despite the administration and absorption of a drug given in a recommended 
dosage. A treatment failure on the other hand is defined as inability of an antimalarial 
agent to clear parasites or to cure clinical symptoms. Factors leading to ‘apparent’ 
treatment failure due to pharmacological factors include: non-compliance of the patient, 
incorrect dosage or poor quality of the antimalarial agent, drug interactions, low 
absorption for instance caused by diarrhea or vomiting, incomplete biotransformation of 
pro-drugs or rapid drug elimination in an individual (World Health Organization 2010). 
Resistance to drugs arises due to two consecutive sequences. In terms of evolution a de 
novo mutation occurs bearing a selection advantage that protects the parasite from the 
antimalarial agent. Having acquired this survival advantage and therefore being less 
sensitive to the drug, this parasite can multiply. If resistant parasites differentiate into 
gametocytes, these parasites can then be transmitted by Anopheles mosquitoes and 
disseminated to a broader population, giving rise to global spread of resistant alleles 
(Wootton et al. 2002)(Roper et al. 2004)(World Health Organization 2010). 
After the large spread of resistance to chloroquine and pyrithamine in the 20th century, 
artemisinin tolerance has spread in Southeast Asia in the past decade (Noedl et al. 
2009)(Dondorp et al. 2010)(Ashley et al. 2014). A small, albeit significant decline in 
early response rates observed in a previous study in Kilifi District indicated that 
artemisinin tolerance may also emerge or spread in sub-Saharan Africa (Borrmann et al. 
2011). Two points are important to note. First, artemisinin tolerance is characterized by 
the ability particularly of young ring stage parasites to survive spikes of high drug 
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concentrations in vitro (measured by the ring stage survival assay, RSA) – this results in 
slower than normal clearance of blood stage parasites from the circulation in vivo and 
thus a delayed clearance phenotype (Witkowski et al. 2013). Second, it appears that this 
phenotype is not due to a single point mutation but to several point mutations in the 
propeller domain of the kelch13 gene and that these mutations have arisen 
independently in different geographical locations (Ashley et al. 2014). 
It is therefore of great importance to contain the spread of resistance against 
artemisinins in an early stage. Monitoring antimalarial drug efficacy and drug 
resistances are therefore essential tools and are implemented on different levels: 
• Ex vivo / in vitro assessment of sensitivities of cultured P. falciparum parasites 
serve as an early warning system to resistances. Different drug concentrations 
are administered to cultured P. falciparum parasites to observe the behavior of 
the parasite to the drug.  
• The research on molecular markers of genetic mutations of the parasite is an 
accurate detection method and allows population-level screening for resistances. 
• The benefit from pharmacokinetic analyses is its power to discriminate between 
true drug resistance and improper or inadequate drug exposure. Furthermore, it 
can uncover the necessity of dose adjustment of the antimalarial agent. 
• The execution of clinical trials measuring clinical and parasitological efficacy of 
medications is a crucial method to notice changes in treatment outcome and has 
become the gold standard for monitoring drug resistances. Genotyping treatment 
failures corrects the efficacy results by distinguishing real treatment failures 
(recrudescences) from new infections and is recommended by the World Health 
Organization as a crucial tool in drug trials. 
1.4.1 Genotyping 
Genotyping is a fundamental tool to distinguish recrudescences from new infections in 
antimalarial drug trials and to assess polymerase chain reaction (PCR) – corrected 
treatment failure rates (World Health Organization 2008). Furthermore, the number and 
types of simultaneously occurring genotypes can be investigated. The pretreatment 
blood sample of an individual is paired to the patient’s blood sample from the day of 
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recurrence of clinical malaria.  Highly polymorphic gene loci of P. falciparum are 
amplified, marked with fluorescent dye and detected by capillary electrophoresis (CE).  
The formerly used gel electrophoresis is being replaced by CE genotyping using 
automated deoxyribonucleid acid (DNA) sequencers. CE has far better resolution 
compared to standard gel electrophoresis. The length of fragments can be determined 
with a precision of one to three base pairs (bp). In contrast, using gel electrophoresis, 
genotypes are aggregated into 20 – 40 bp bins and as a result misclassifications can 
occur. CE also shows an advantage in detecting multiple infections (Falk et al. 2006) 
and in analysing samples with high parasite densities (Liljander et al. 2009). However, 
the main drawback of CE genotyping is the high cost of automated sequencers. Thus, 
gel electrophoresis remains an important tool in field settings when CE genotyping is 
not available, especially as the efficiency of differing recrudescent genotypes from new 
infections is alike whether gel electrophoresis or CE is performed (Liljander et al. 
2009). 
Merozoite surface protein 2 
Highly polymorphic gene loci encoding merozoite surface proteins such as merozoite 
surface protein 1 (msp-1), merozoite surface protein 2 (msp-2) or glutamine-rich protein 
(GLURP) show above-average genetic diversity due to diversifying immune selection 
pressure. This renders msp-1, msp-2 and GLURP suitable for genotyping of 
P. falciparum field isolates. As msp-2 shows the highest discriminatory power (Basco et 
al. 2004), it is an ideal genetic marker and was used in this study to investigate 
treatment failure rates.  
The exact function of msp-2 has not yet been identified but studies indicate it to be 
important when merozoites bind to erythrocytes. Moreover, it has been suggested that 
surface proteins play a variety of roles while entering an erythrocyte and afterwards 
(Boyle et al. 2014). 
Msp-2 is located on chromosome 2 (Wickham et al. 2003). The genetic locus coding for 
msp-2 can be sub-classified into five blocks as can be seen in Figure 2. Block one and 
five are highly conserved N- and C-terminal regions. Block two and four are non-
repetitive variable regions and block three consists of a highly polymorphic central 
region (Smythe et al. 1991) (Kiwanuka 2009), which occurs as one of two dimorphic 
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allelic families: 3D7-type alleles and D10-type alleles (Smythe et al. 1991). In literature, 
3D7 is often referred to as IC-1 and D10 as FC27 (Wickham et al. 2003). The sequence 
diversity within each allelic family concerns the repeat regions and the regions flaking 
these (MacRaild et al. 2015). The allelic families differ in nucleotide sequences on the 
one hand and in the quantity of repetitive sequences on the other hand (Joshi et al. 
2007). Below, these individually sized fragments, which can be allocated either to 3D7 
or D10, will be referred to as genotypes.  
 
 
Figure 2: Scheme of the genetic composition of the merozoite surface protein 2 on chromosome 
2. Block 1 and 5 (yellow) are highly conserved terminal regions, whereas block 2 and 4 (red) 
are non-repetitive variable regions. Block 3 is composed as highly polymorphic central region 
and occurs as 3D7-type allele (green) or as D10 type (blue) allele.  
1.5 Aim of the study 
In this pilot study, I examined 63 paired samples from the WANECAM-trial with the 
title “A Phase IIIb / IV comparative, randomized, multi-centre, open label, parallel 3-
arm clinical study to assess the safety and efficacy of repeated administration of 
pyronaridine-artesunate, dihydroartemisinin-piperaquine or artemether-lumefantrine 
or artesunate-amodiaquine over a two-year period in children and adult patients with 
acute uncomplicated Plasmodium sp. malaria.“ by high resolution capillary 
electrophoresis genotyping of P. falciparum msp-2. 
For the first time, malaria samples from Bobo-Dioulasso, Burkina Faso were examined 
by high resolution CE genotyping. Genotyping has become an important method in 
antimalarial drug trials and it was therefore of major interest to establish this method for 
samples from the WANECAM-trial. My hypothesis was that it was possible to establish 
high resolution CE genotyping for these samples. My main study aim was to distinguish 
Introduction 
 
 
12 
recurrences in whether they appeared due to a new infection or due to recrudescence. 
Secondary outcomes concerned the assignment of recrudescences to treatment arms and 
to certain alleles. Moreover, allele frequencies were investigated.  
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2 Materials & Methods 
2.1 Materials 
2.1.1 Samples 
Filter paper blood samples were taken from patients from Bobo-Dioulasso, who were 
enrolled in the WANECAM drug-trial. Each patient was followed-up for 42 days and 
on each visit finger prick blood samples were collected on Whatman™ 3MM filter 
papers. The filter papers were dried and stored separately in sealed plastic bags to 
prevent cross contamination. The bags, containing silica gel to prevent humidity, were 
stored at room temperature. 63 paired samples from patients, who had suffered a 
treatment failure within 42 days, were placed to my disposal by my Burkinian 
colleagues. 59 of the 63 paired samples derived from the study site in Sakaby, including 
48 paired samples from the AL study arm, 6 paired samples from the DP study arm and 
5 paired samples from the PA study arm. 4 paired samples, all from the AL study-arm, 
derived from the study site in Colsama. All samples were transported by plane to 
Tübingen, Germany, and analysed in the laboratory of Professor Borrmann. 
2.1.2 Enzyme 
Table 1: Enzyme used for PCR. 
Thermo Scientific      Taq DNA Polymerase (recombinant) 5 U / µl, 500 U 
 
2.1.3 Synthetic oligonucleotides 
Table 2: Synthetic oligonucleotides. 
Name Company Sequence Vol. for 
100 pmol / µl 
Molarity 
dNTP 
Mix 
Thermo 
Scientific 
dNTP Mix Molecular Biology 
Grade 
 2 mM 
each 
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Msp-2 
S1 
Eurofins 
Genomics 
5’-gtctcttcttataatatgagtataaggagaa 
3’(31) 
178 µg 18.5 nmol 
Msp-2 
S2 
Eurofins 
Genomics 
5’-gaaggtaattaaaacattgtc 3’ (21) 150 µg 23.1 nmol 
Msp-2 
S3 
Eurofins 
Genomics 
5’-gagggatgttgctgctccacag 3’ 
(22) 
165µg 24.3 nmol 
M5 Eurofins 
Genomics 
FAM 5’-gcattgccagaacttgaa 3’ 
(18) 
277µg 45.8 nmol 
N5 Eurofins 
Genomics 
JOE 5’-ctgaagaggtactggtaga 3’ 
(19) 
409µg 62.1 nmol 
 
2.1.4 Size standards 
Table 3: Size standards. 
Size Standard Name Company 
100 bp DNA ladder N323L Size Standard New England Biolabs 
Gene Scan™ –500, ROX™ Size Standard Applied Biosystems 
 
2.1.5 Antimalarial agents 
Table 4: Antimalarial agents. 
Antimalarial Agent Registered Trade Name Company 
Artemether-lumefantrine Coartem® Novartis Pharmaceutical 
Cooperation 
Dihydroartemisinin-
piperaquine 
Eurartesim® Sigma-Tau Pharma 
Pyronaridine-artesunate Pyramax® Shin Poong Pharmaceutical 
 
2.1.6 Chemicals 
Table 5: Chemicals. 
Chemical Name Company 
Boric acid for analysis  Emsure Acs Iso Reag. Ph Eur Merck 
KGaA Darmstadt 
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86 – 88 % Ethylendiaminetetraacetic acid 
(EDTA) C10H12N2Na4O8 
Carl Roth GmBH + Co KG Karlsruhe 
3130 POP-7™ Performance Optimized 
Polymer 
Applied Biosystems 
Hi-Di™ Formamide Applied Biosystems 
SeaKem LE Agarose LONZA 
SybrGreen® I 2 x 500 µl Biozym 
Trishydroxylmethylaminomethane  
Tris Ultrapure C4H11NO3 
AppliChem Panreac ITW companies, 
Darmstadt 
 
2.1.7 Buffers, media and solutions 
Table 6: Buffers, media and solutions. 
Content Company 
10X Sequencer Buffer with EDTA Applied Biosystems 
10X Taq – buffer with (NH4)2SO4 Thermo Scientific 
25 mM MgCl2 Thermo Scientific 
LiChrosolv® Water for Chromatography Merck KGaA 
Loading – buffer Life technologies 
 
2.1.8 Disposables 
Table 7: Disposables. 
Name Company 
Eppendorf Sterile Biopur 1.5 ml tubes Eppendorf 
Micro Tubes 0.5 ml, PP Sarstedt 
Parafilm “M” Laboratory Film Pechiney Plastic Packaging 
PCR SingleCap 8er-SoftStrips 0.2 ml Biozym Scientific  
Plate Septa 96-Well Applied Biosystems 
Quali-PCR-Plates G060/H-1E-OA Kisker Biotech 
SafeSeal Micro Tube 2 ml, PP Sarstedt 
TipOne 200 µL Graduated Filter Tip Starlab 
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(Sterile) 
 
2.1.9 Equipment 
Table 8: Equipment. 
Equipment Name Company 
3130 / 3130 xl Genetic Analyzers Applied Biosystems 
Bench DNA/RNA UV-Cleaner  
UVC/T-M-AR 
Kisker Produkte für Biotechnologie 
Centrifuge Galaxy Mini VWR International 
Centrifuge Megafuge 1.0R Heraeus 
Mastercycler epgradient S Eppendorf 
Eppendorf Research 1000 µl Pipettes Eppendorf 
Eppendorf Research 200 µl Pipettes Eppendorf 
Eppendorf Research 10 µl Pipettes Eppendorf 
Eppendorf Research 2.5 µl Pipettes Eppendorf 
Freezer - 18 °C: Premium NoFrost Liebherr 
Heater and Magnet Mixer MR 3001 Heidolph 
HG Tuning-Fork Scale Max/d 2000/0.01g  Vibra Shinko Denshi 
Lab dancer IKA 
MicroAmp™ Optical 96-Well Reaction 
Plate 
Applied Biosystems 
neoBlock – HeizerDuo 2-2504 neoLab 
Plate Septa 96-Well Applied Biosystems 
PowerPac™ Basic 300V/400mA/75 W Bio-Rad  
Refrigerator: Premium Liebherr 
Run 3130 Data Collection v 3.0 Properties Applied Biosystems 
Subcell GT Cell Electrophoresis Systems Bio-Rad 
Vortex Mixer VM 300 neoLab 7-2020 
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2.1.10 Software 
Table 9: Software. 
Name Company 
BioDocAnalyze Biometra 
Excel Microsoft 
Gene Mapper® v 4.0 Properties Applied Biosystems 
GraphPad PRISM® 7 GraphPad Software, Inc. 
Mendeley Elsevier 
Powerpoint Microsoft 
Word Microsoft 
 
2.2 Methods 
2.2.1 Study design 
The WANECAM drug trial with the title “A Phase IIIb / IV comparative, randomized, 
multi-center, open label, parallel 3-arm clinical study to assess the safety and efficacy 
of repeated administration of pyronaridine-artesunate, dihydroartemisinin-piperaquine 
or artemether-lumefantrine or artesunate-amodiaquine over a two-year period in 
children and adult patients with acute uncomplicated Plasmodium sp. malaria.“ was 
undertaken in Burkina Faso, Guinea Conakry and Mali (Clinical trial registry: 
PACTR20115000286876). 744 patients were included in Bobo-Dioulasso, of which 296 
were recruited for AL and 224 for DP and PA, respectively. DP and PA were compared 
to AL. The comparator artesunate-amodiaquine (ASAQ) was not used in Bobo-
Dioulasso. The enrolment period in Bobo-Dioulasso took place from August 2012 until 
December 2015. Each patient was followed for two years and treated with the same 
study drug if a new malaria episode occurred.  
2.2.2 Study endpoints 
The primary objective of the WANECAM study was to compare the incidence rate of 
uncomplicated malaria in children and adults who were treated repeatedly over a period 
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of two years with the same ACT. A primary efficacy endpoint was to show the non-
inferiority of PA and DP compared to AL or ASAQ.  
One of several secondary endpoints was to assess the PCR-corrected treatment failure 
rate by genotyping. The study investigated whether recurrent infections occurring 
within a follow-up period of 42 days derived from new infections or from persistent 
primary infections (recrudescences). 
2.2.3 Study site 
Burkina Faso is a landlocked West African country, which borders clockwise on Niger, 
Benin, Togo, Ghana, Ivory Coast, and Mali. Its surface is 273,000 km² and in 2016, its 
population was estimated at 18,634,000 inhabitants. The GDP per capita in 2014 was of 
725 US $ (UNdata 2016f). Burkina Faso’s official language is French but many local 
languages such as Dioula, Mooré and Foufouldé are spoken.  
Burkina Faso was politically stable for many years. This changed when the former 
president Blaise Compaoré, who is known to have assassinated his friend, revolutionist 
and national hero Thomas Sankara, was about to change a law that would have allowed 
him a fifth mandate after having been in power for 27 years. Strikes and demonstrations 
climaxed in the resignation of Compaoré on October 31st, 2014 (ZEIT ONLINE 2017b). 
An interim government was installed but it suffered a military coup on September 23rd, 
2015 in which its transitional president Kafando was held captured amongst others. The 
coup was organized by the former presidential guard under the lead of Gilbert Diendéré 
but was calmed by the agreement, which determined that Compaoré’s allies were 
allowed to run for the presidential office during the upcoming elections (ZEIT ONLINE 
2017c)(LeMonde 2017e). Finally, on November 29th, 2015 Roch Marc Christian Kaboré 
from the People’s Movement for Progress won the election with nearly 53.5 % and 
became the current president of Burkina Faso (FAZ 2017d). 
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Figure 3: Map of Westafrica, highlighting the city Bobo-Dioulasso. © OpenStreetMap 
contributors 
Bobo-Dioulasso is Burkina Faso’s second largest city after the capital Ouagadougou 
and the economic heart of the country. It is situated in the region of Hauts-Bassins in the 
province of Houet about 350 km from Ouagadougou. It has a population of 
approximately 813 610 inhabitants in the census of 2012 (DGESS 2014)(ISND 2017g). 
The rainy season arises from June to November, which leads to a malaria transmission 
time of approximately eight months in Bobo-Dioulasso (Tinto et al. 2016). The annual 
entomological inoculation rate was estimated by 60 infective bites per person per year 
(Tinto et al. 2002), which characterizes mesoendemic transmission (Kiwanuka 2009). 
A first study site was installed with the beginning of the study in 2012 in Sakaby, a 
small town in the northern surroundings of Bobo-Dioulasso. To accelerate the 
recruitment rate, a second study site was established in Colsama in the southwestern 
part of Bobo-Dioulasso. Both study sites were established in local dispensaries. To see 
were the study sites were located, see Figures 4 – 6. 
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Figure 4: Streetmap of Bobo-Dioulasso indicating the local dispensary CSPS de Colsama in the 
west of Bobo-Dioulasso. © OpenStreetMap contributors. 
 
Figure 5: Photography of the local dispensary and study site, CSPS Colsama, Bobo-Dioulasso. 
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Figure 6: Streetmap of Bobo-Dioulasso indicating the local dispensary CSPS de Sakaby in the 
north of Bobo-Dioulasso. © OpenStreetMap contributors 
2.2.4 Patients  
Patients coming to the study sites lived within a radius of approximately zero to four 
kilometers. They arrived mostly by foot, but a few were driven by a fieldworker. Each 
patient was enrolled in the study for two years of follow-up.  
The patients were blindly assigned to treatment arms. If patients fulfilled all inclusion-
criteria, they were assigned to the lowest available number on the randomisation list. 
Every number on the randomisation list contained an attribution to one of the following 
study medications: AL, DP or PA. Each patient was treated for three consecutive days. 
On each day of treatment and during every follow-up visit a physician conducted a 
physical examination, a questionnaire was answered, blood smears were analysed and 
filter paper blood samples were taken. Biochemical and hematological parameters were 
investigated on day 0, 3 and 28. An electrocardiogram (ECG) was written on day 0 and 
day 2 with special attention to significant QT-prolongations or arrhythmias. Table 10 
illustrates the visit schedule for enrolled patients. 
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Table 10: Visit schedule for enrolled patients. 
Day 0 1 2 3 7 14 21 28 35 42 
Treatment þ þ þ        
Clinical 
examination  
þ þ þ þ þ þ þ þ þ þ 
Malaria 
blood smears 
þ þ þ þ þ þ þ þ þ þ 
Filter paper 
samples 
þ þ þ þ þ þ þ þ þ þ 
Biochemistry þ   þ    þ   
ECG þ  þ        
 
The patients or parents in case of paediatric patients were asked to come to the clinic at 
any time if they felt ill. If a second clinical malaria infection occurred within the follow-
up phase of 42 days, this was managed as a treatment failure. If a second clinical 
malaria infection occurred after the follow-up period of 42 days, the event was 
registered as a consecutive malaria episode. In case of a new uncomplicated malaria 
episode, patients were treated with the same medication as in their first episode.  
More details on the WANECAM-trial can be seen in the appendix. 
2.2.5 Pilot study – summary 
I familiarized myself with the protocol for high-resolution capillary electrophoresis 
genotyping at the AG Borrmann laboratory, Institute for Tropical Medicine in 
Tübingen, to analyse 63 paired samples that were assigned to me by my Burkinian 
colleagues at the end of my stay. All samples derived from patients who were enrolled 
in the WANECAM-study in either Sakaby study site or Colsama study site.  
I examined these 63 paired samples from Bobo-Dioulasso to differentiate 
recrudescences from new infections in treatment failures before day 42. A new infection 
is defined as a consecutively appearing parasitaemia with no common allele between 
day 0 and the day of recurrence. A recrudescence is defined as persistence of at least 
one allele from day 0 (World Health Organization 2008).  
I extracted DNA from the filter paper blood samples and then I amplified the DNA in a 
nested polymerase chain reaction (Figure 7): First, I performed a primary PCR (pPCR) 
using primers that bind to the conserved flanking regions of block 3 of msp-2. Next, I 
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performed a secondary PCR (sPCR) with family-specific primers to amplify variable-
size fragments using one fluorescence-marked primer per family-specific PCR reaction. 
I determined presence or absence of the PCR product by agarose gel electrophoresis to 
verify the success of my PCR reaction. In case of a positive result, I further analysed 
these samples in an automated sequencer (3130 / 3130 xl Genetic Analyzers, Applied 
Biosystems). I used the software GeneMapper® 4.0 for examining the results and 
inspecting the electropherograms. Genotying was performed in accordance with the 
genotyping protocol from Falk et al. (2006). 
2.2.6 DNA extraction 
The first step of my experimental laboratory work was to extract the DNA contained in 
dried filter paper blood samples, which I had collected from patients in Bobo-Dioulasso. 
The DNA extraction was performed underneath a laboratory hood used exclusively for 
genomic DNA (gDNA) extraction. The extraction was performed wearing gloves. To 
begin with the extraction, I cut two to three stripes of about 3 - 5 mm length and 1 mm 
width into a 0.5 µl tube. With each new sample I changed gloves and disinfected the 
scissors with 95 % alcohol. I introduced one DNA-free tube as a negative control, 
which was handled exactly as the other tubes. I added 100 - 150 µl of methanol to each 
tube to fix the DNA and left the tubes open overnight, which caused the methanol to 
evaporate. To lower the risk of contamination, the hood was closed during this step. The 
next morning I adjusted a heater to 100 °C and I added 100 – 150 µl of nuclease-free 
water to the tubes.  I closed all lids of the tubes and boiled them for 15 minutes. Within 
this time I vortexed each tube at least three times for 20 – 30 seconds starting after 5 
minutes of heating. Heating and vortexing the tubes caused the DNA to pass from the 
dried filter paper into the water so that I could select and amplify Plasmodium DNA in 
the following steps. 
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Figure 7: Nested PCR, consisting of pPCR (steps 1 – 3) and sPCR (steps 3 – 5). P. falciparum 
DNA is heated, thereby the hydrogen bonds dissolve and both DNA strands can be used as 
template for new amplification (step 1). Primers from pPCR (red) bind to the flanking regions 
of block three of msp-2 and Taq-polymerase begins the amplification using nucleotides. As the 
pPCR primers bind to the flanking region of block three of msp-2, the amplicon is shorter than 
the original template (step 3). In sPCR, the short amplicon from step 3 is heated again. 
Hydrogen bonds dissolve once more and now (step 4) fluorescently marked primers from sPCR 
(green) bind to block three of msp-2. Taq-Polymerase begins amplification and thereby, block 
three of msp-2 is amplified. This principle is applied to both 3D7 and D10 type alleles as 
primers for both families are used in nested PCR. 
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2.2.7 Nested PCR: primary polymerase chain reaction 
After DNA extraction, I used a primary polymerase chain reaction (PCR) to amplify a 
fragment from block 3 of the msp-2 gene. All primers were identical to the primers 
reported by Falk et al. (2006). All primers were set up for 100 pmol / µl. 
The dNTP-Set was mixed using equal amounts of deoxyadenosine, deoxythymidine, 
deoxycytidine and deoxyguanosine. To prevent contamination, I formulated the 
mastermix (Table 11) in a second, malaria-naive laboratory. Here, I worked underneath 
a flow hood that was ultraviolet-irradiated after usage and kept my agents on an iced 
tablet. I first pipetted H2O into a sterile tube. Then, I added 10 X buffer, MgCl2, dNTPs 
2 mM, primer S2 10 mM, primer S3 10 mM and finally the frozen Taq-polymerase. All 
agents can be seen in Table 11. I vortexed this mastermix and distributed it into PCR 
SingleCap 8er- SoftStrips 0.2 ml tubes with 45 µl of mastermix each.  
Table 11: Agents for mastermix of pPCR. 
Agent Amount in µl 
H2O 31.25 
10 X buffer 5.0 
MgCl2 3.0 
dNTP Mix 2mM 5.0 
Primer S2 10 mM 0.25 
Primer S3 10 mM 0.25 
Taq-polymerase 0.15 
 
I added two positive controls containing a D10-type allele and a 3D7-type allele and 
two negative controls: the first one containing the DNA-free extraction water, the 
second one containing the pPCR-mastermix without DNA. I pipetted 5 µl of each 
extracted DNA into all other tubes and placed them into the cycler. The cycler was 
programmed as listed in Table 12. 
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Table 12: Cycler's programming for pPCR. No. stands for number. 
No. of cycles Time (in minutes) Temperature 
1 5:00 94 °C 
30 0:30 94 °C 
 2:00 55 °C 
 2:00 70 °C 
1 7:00 72 °C 
    4 °C 
 
2.2.8 Nested PCR: secondary polymerase chain reaction  
The following agents were needed for the mastermix of the secondary PCR (sPCR): 
Table 13: Agents for mastermix of sPCR. 
Reagent Amount in µl per sample 
H20 31.6 
10 X buffer 5.0 
MgCl2 3.0 
dNTP Mix 2mM 5.0 
Primer S1 10mM 2.0 
Primer M5 10mM 1.0 
Primer N5 10mM 1.0 
Taq 0.4 
 
The fluorence-labeled primers M5 and N5 were stored in the dark to ensure 
conservation. I mixed the mastermix for the sPCR in the second, malaria-naive 
laboratory underneath a flow hood, which was ultraviolet-irradiated after usage, and 
assorted my agents on an iced tablet. To produce the sPCR-mastermix, I added H2O, 10 
X buffer, MgCl2, dNTP 2mM, primer S1, labeled primers M5 and N5 and Taq as listed 
in Table 13. I vortexed the sPCR-mastermix and distributed it into PCR SingleCap 8er-
SoftStrips 0.2 ml with 49 µl of mastermix. I added one new negative control with 
sPCR-mastermix and closed this tube’s lid at once. Back in the lab, I added 1 µl of the 
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pPCR-amplificates each to the tubes containing the sPCR-mastermix. I shut the tubes 
and put them into the cycler starting the program listed in Table 14. 
Table 14: Cycler's programming for sPCR. 
No. of cycles Time (in minutes) Temperature 
1 2:00 94 °C 
44 0:30 94 °C 
 0:45 50 °C 
 1:30 70 °C 
1 10:00 70 °C 
    4 °C 
 
2.2.9 Agarose gel electrophoresis 
A 1.5 % agarose gel electrophoresis was assembled to determine whether DNA was 
successfully amplified. The agarose gel forms a matrix in which amplified, negatively 
charged DNA fragments can be separated by size by use of an electric field. By 
exposure to ultraviolet light, bands can be visualized and compared to an added size 
standard (so called, DNA ladder), which enables the investigator to estimate the size of 
DNA fragments. 
Preparation:  
• SYBRGreen® I 2 x 500 µl was diluted 1:100 in dimethylsulfoxide underneath a 
flow hood and portioned into small aliquots to inhibit a loss of function due to 
frequent freeze-thawing. The portions were stored at - 20 °C.  
• The blue loading buffer was prepared with 0.1 g bromphenolblue, 0.1 g 
xylencyanol, 40 g glycerol, 2 ml 0.5 M EDTA on 100 ml H2O and stored at 
4 °C.  
• The base pair size standard was prepared with 10 µl 100 bp DNA ladder, 70 µl 
H2O and 20 µl of blue loading buffer. 
• Orange G loading buffer was prepared with 20 ml glycerol, 0.01 g Orange G and 
1 ml 500 mM EDTA. 
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• The 1 X TBE buffer was prepared with 216 g TRIS, 14.88 g EDTA and 111.2 g 
boric acid and dissolved into 2 l of deionized water. 10 X TBE buffer was 
assembled by diluting 1 X buffer 1:10 with deionized water.  
To mix the agarose gel, I used a glass container of minimum 250 ml and 1.5 g of 
agarose to 100 ml of 10 X TBE buffer. A magnet mixer stirred the mixture while it 
boiled for several minutes in a microwave until the liquid became clear. I filled the 
liquid agarose gel into a tray and let it harden.  
I established a loading mix by mixing 2.5 µl of blue loading mix, 1.5 µl of purified 
water and 1.0 µl of SYBR®Green per sample, respectively. SYBR®Green binds to 
double stranded DNA and serves to visualize DNA in gel electrophoresis. It emits green 
light at λmax = 520 nm when excited with ultraviolet light.  
Table 15: Loading mix. 
Reagent Amount in µl 
Blue loading buffer 2.5 
Bidest Water 1.5 
SYBR®Green 1.0 
 
I placed the hardened agarose gel into a buffer solution and pipetted 3.5 µl of size 
standard and 1 µl of SYBR®Green into the first pouch of the gel. I filled the other 
pouches with 5 µl of loading-mix and 5 µl of sPCR product. Then, I applied an electric 
field at 100 Volt and examined the gel after 25 – 35 minutes underneath ultraviolet 
light.  
Lanes with DNA-positive samples were recognized due to yellow bars, which appear 
when the agarose gel is excited by ultraviolet light (Figure 8). These DNA-positive 
samples were then examined through CE and the resulting data can be inspected by the 
GeneMapper® software as electropherograms. In lanes with DNA-negative samples no 
yellow bar appeared when excited by ultraviolet light. These DNA-negative samples 
were examined a second time in an agarose gel using 3 µl of sPCR amplification-
product. Figure 8 illustrates an agarose gel, which shows the DNA ladder in lane one, 
different intensities and quantities of bars in lanes two to seven and no bar in lane eight 
meaning that no, or very little PCR product, was visible in lane eight. 
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Figure 8: Fluorescenct bands in agarose gel. It is well demonstrated how the DNA size 
standard in lane one spreads into different bands. Each band stands for a differently sized DNA 
fragment. In lane five, one single band can be seen, whereas in lane two, three, four, six and 
seven, several bands are visible. No band and therefore no DNA shows in lane eight. 
2.2.10 Capillary electrophoresis 
Capillary electrophoresis (CE) is performed in form of a modified Sanger sequencing 
method: After having conducted pPCR, the resulting DNA fragments were marked by 
fluorescent dye due to fluorescently marked primers in sPCR. These fragments were 
then separated in a separation matrix (3130 POP-7™ Performance Optimized Polymer) 
within fine capillaries by an automated DNA sequencer (3130xl Genetic Analyzers, 
Applied Biosystems). Their sizes in base pairs (bp) were estimated by comparing the 
migration time of the analysed fragment with the migration time of an internal 
fluorescent size standard (ROX-500). The fragments and the size standard were made 
visible by excitation with a laser. The allele-types 3D7 and D10 were distinguished 
because two differently coloured allelic-type-specific fluorescent dyes were used for 
sPCR to label one primer per family-specific primer pair. A dedicated software 
(GeneMapper®) analysed the information containing both fragment size and affiliation 
to either 3D7 or D10 and displayed it in form of electropherograms (Liljander et al. 
2009).  
I performed CE only on samples that had shown a DNA-positive bar in agarose gel 
electrophoresis. Hi-Di™ was portioned into parts of 500 µl and frozen beforehand. I 
diluted the sPCR product with DNA-free water (LiChrosolv®) 1:400 at first. Then, I 
1 2 3 4 5 6 7 8 
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pipetted 10 µl fluorescent size standard ROX-500 (range 50 – 500 bp), 2.5 µl of the 
diluted sPCR product and at last 10 µl of HiDi™ into each pit of a 96-well sequencer 
plate. I centrifuged the 96-well-plate to remove air bubbles and put the plate into its 
attachment. I placed it in the sequencer and chose the GeneScan® program for capillary 
electrophoresis. If the capillary electrophoresis did not detect any fragments, I diluted 
the sPCR product consecutively 1:200, 1:40, 1:5 and 1:1 until a fragment could be 
detected. 
2.2.11 Interpretation of electropherograms 
To be able to read the data that the sequencer produces, the GeneMapper® software 
produced electropherograms. On the x-axis one can see the length of the DNA-fragment 
in base pairs (bp), on the y-axis the detected intensity in relative fluorescent units (rfu). 
The red peaks derive from the size standard, green peaks belong to 3D7-type alleles and 
blue peaks to D10-type alleles. In the program, one can select the peak and read the 
exact length of base pairs as well as the intensity.  
Figure 9 shows one single 3D7-type (green peak) allele with a length of 326 bp and an 
intensity of 646 rfu.  
 
Figure 9: One single 3D7-type allele. X-axis shows length of detected PCR-fragments in bp. Y-
axis depicts detected intensity in rfu. 
To evaluate electropherograms with more than one peak and to decide on whether a 
peak can be interpreted as an allele, the cut-off was defined. The cut-off is the intensity 
above which a peak is interpreted as an allele. As described by Messerli et al. (2016), I 
defined the cut-off as the intensity that consists of 10 % of the highest peak.  
3200   - 
800   - 
1600   - 
2400   - 
4000   - 
240 280 320 360 400 440 480 
4800   - 
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In Figure 10 one high peak from a 3D7-type allele can be seen with a length of 276 bp 
and an intensity of 3480 rfu. A second peak of 344 bp must not be interpreted as an 
allele because its intensity is of 310 rfu, which makes it < 10 % of the highest peak. 
 
Figure 10: Two genotypes? Defining a peak. X-axis shows length of detected PCR-fragments in 
bp. Y-axis depicts detected intensity in rfu. 
Figure 11 shows an electropherogram with six peaks of which two were counted as 
genotype: the highest peak D10 417 bp with an intensity of 515 rfu (blue peak) and the 
second highest 3D7 277 bp (green peak). The other four peaks showing an intensity of 
< 515 rfu were not counted genotypes.  
 
Figure 11: Several peaks. X-axis shows length of detected PCR-fragments in bp. Y-axis depicts 
detected intensity in rfu. 
Control mechanisms 
Each step during the laboratory work produced a negative control. A broad 
contamination would be positive in agarose gel electrophoresis by showing a band of 
the same size in each row. The much more precise method of CE genotyping would 
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show a peak at a certain fragment size in each electropherogram. An inconspicuous 
negative control as in Figure 12 shows the red size standard peaks but no peaks in other 
colours.  
 
Figure 12: Inconspicuous negative control. X-axis shows length of detected PCR-fragments in 
bp. Y-axis depicts detected intensity in rfu. 
A 3D7-type positive control with 265 bp and a D10-type positive control with 358 bp 
was included in the study and are shown in Figure 13 and 14. 
 
Figure 13: 3D7-type positive control. X-axis shows length of detected PCR-fragments in bp. Y-
axis depicts detected intensity in rfu.  
 
Figure 14: D10-type positive control. X-axis shows length of detected PCR-fragments in bp. Y-
axis depicts detected intensity in rfu. 
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2.2.12 Statistical evaluation 
After having noted all genotypes in an Excel table, I started the so-called process of 
binning. Thanks to the high sensitivity of automated CE and given that a coding region 
is genotyped, fragment sizes differed by multiples of 3 bp (Falk et al. 2006). I therefore 
manually selected 3 bp bins and evaluated recrudescence rates by comparing genotypes 
that had occurred in the sample at baseline (day 0) with genotypes from the samples of 
the day of recurrence. Furthermore, I analysed allele frequencies of the population at 
baseline by taking all baseline genotypes into account. The mean multiplicity of 
infection (MOI) was calculated as MOI = !"!#$ !"#$%& !" !.!"#$%&"'() !"#$%&'"(!"#$%& !" !"#$%$&' !"# !"#!"#$   (Mwingira et 
al. 2011). The theoretical probability of being infected twice with the same genotype 
can be calculated as P= 𝑝i2 with pi being the frequency of the analysed genotype. The 
heterozygosity of infection (HE) is an indicator of risk of misclassification when certain 
genotypes in a population occur in a high allele frequency. I calculated HE for the 
genotype that appeared with the highest allele frequency as HE = [n/(n-1)][(1- 𝑝i2)] 
with n = number of samples and pi = frequency of the genotype (Schoepflin et al. 2009).  
I calculated the mean, median and standard deviation of selected data with a 95 % 
confidence interval (CI) using Excel. I used GraphPad PRISM® 7 to build descriptive 
graphs.  
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3 Results 
The following chapter is divided into five parts: First, I will display a flow chart as well 
as examples for recurrences and reinfections on electropherograms. Then, I will present 
baseline characteristics of the investigated patients. I will discuss allele frequencies in 
the baseline population and then, I will focus on recurrences. Finally, I will present 
results on the mean multiplicity of infection and the heterozygosity of infection. 
3.1 Implementing msp-2 genotyping of 63 paired samples       
from Bobo-Dioulasso 
As can be seen in Figure 15 I analysed 126 samples corresponding to 63 pairs of 
isolates from baseline (day 0) that were retrieved before the administration of 
medication and from the day of asexual parasite recurrence. 47 (74.60 %) were 
successfully amplified. The data, which is analysed and discussed below derives 
therefore from these successfully amplified 47 paired samples.  
The paired samples contain one baseline sample (day 0) that was retrieved before the 
administration of medication and one sample from the day of recurrence. 16 paired 
samples could not be successfully amplified. Even after multiple attempts of re-
extracting DNA, amplifying and genotyping, no PCR product could be detected in the 
agarose gel electrophoresis. Two of the positive paired samples were excluded due to 
stutter peaks.  
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Figure 15: Flow chart demonstrating amount of positive and negative samples. 
I will use the following examples for illustrating the type of data obtained and how the 
data were interpreted for classifying recurrent infections into either recrudescent 
infections (i.e., infections that appeared to persist despite treatment) or new, secondary 
infections. Figure 16 and Figure 17 show an example for a sample pair that represents a 
new infection. Each electropherogram shows a different genotype. The baseline 
electropherogram of day 0 shows the genotype 3D7 241 bp, whereas the 
electropherogram of the day of recurrence shows a genotype of 3D7 268 bp. Both peaks 
represent 3D7-type alleles as the colour of the peaks is green. 
 
Figure 16: New infection - day 0. X-axis shows length of detected PCR-fragment in bp. Y-axis 
depicts detected intensity in rfu. 
 
63 paired samples (100 %)  
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Figure 17: New infection - day of recurrence. X-axis shows length of detected PCR-fragment in 
bp. Y-axis depicts detected intensity in rfu.  
Figure 18 and Figure 19 on the other hand demonstrate an example for a recrudescence. 
The electropherogram from baseline in Figure 18 shows a co-infection of two different 
genotypes: D10 336 bp (blue) and 3D7 272 bp (green).  
 
Figure 18: Recrudescence-pair: day 0. X-axis shows length of detected PCR-fragments in bp. Y-
axis depicts detected intensity in rfu. 
The day of recurrence in Figure 19 indicates a recrudescence due to the persistence of 
genotype D10 336 bp (blue peak). Additionally, a co-infection with new genotypes 
D10 417 bp (blue) and 3D7 252 bp (green) can be seen on the day of recurrence.  
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Figure 19: Recrudescence-pair: day of recurrence. X-axis shows length of detected PCR-
fragments in bp. Y-axis depicts detected intensity in rfu. 
3.2 Baseline characteristics 
The baseline characteristics of the 47 patients are illustrated in Table 16. Due to the 
small sample size and the unbalanced number per treatment arm, statistical tests could 
not be carried out.  
Table 16: Baseline characteristics of enrolled patients. SD stands for standard deviation. 
Baseline 
characteristics 
AL 
n = 36 
DP 
n = 4 
PA 
n = 5 
Gender male / 
female (%) 
17 / 19  
(47.2) / (52.8) 
3 / 1 
(75) / (25) 
2 / 3 
(40) / (60) 
Age mean 
(median) in years 
± SD, range 
7.4 (6) ± 5.7, 
2 - 34 
2.5 (2.5) ± 1.1, 
1 – 4 
6.8 (7) ± 4.3, 
2 – 14 
Weight mean 
(median) in kg 
± SD 
22.3 (18.7) ± 11.4 11.4 (11.6) ± 1.1 22.3 (20.9) ± 0 
Parasitaemia 
mean (median) in 
µl  
53 631 (28630) 75 350 (55090) 91 644 (95620)  
Hemoglobin mean 
(median) in g / dl 
± SD 
10.4 (10.4) ± 1.3 9.1 (9.6) ± 1.3 10.1 (10.6) 
± 1.11 
Axillary 
temperature mean 
(median) in °C 
± SD 
37.7 (37.7) ± 1.1 38.4 (38) ± 0.8 39.1 (38.8) ± 0.6 
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Two patients showed gametocytaemia in their baseline sample, which in both cases 
disappeared before the day of recurrence. Of these two patients, one was found to have 
a recrudescence and one a new infection. 
3.3 Allele frequency 
I calculated allele frequencies by assigning all genotypes that were observed in the 
baseline samples by their size in base pairs into 3 bp sized “bins”. (E.g., fragments of 
the sizes 3D7 280 bp, 281 bp and 282 bp were assigned to the bin 3D7 281 bp.) Then, I 
calculated the frequency of each genotype.  
All genotypes that occur above 5 % belong to D10-type alleles 
One particular question after having calculated the distribution and frequencies of 
genotypes was whether certain genotypes were overrepresented. An initial interesting 
observation was that all genotypes that occurred above 5 % in the baseline population 
belonged to D10-type alleles (Fig. 20).  
 
Figure 20: Allele frequency in baseline population. Frequencies > 5 % are indicated with exact 
allele frequency, with fragment length and allelic type. The green colour depicts 3D7-type 
alleles and the blue colour represents D10-type alleles. Lengths of fragment are indicated in bp. 
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Then, I noticed that results showed a total of 50 different genotypes being distributed 
between 35 3D7-type alleles and 15 D10-type alleles. However, 49.44 % of infections 
were caused by D10-type alleles. 
When looking at allele frequencies of the two allelic families separately from one 
another, the polymorphic nature of 3D7 alleles with 35 alleles can be easily appreciated 
(Fig. 21). There is no striking frequency within 3D7-type alleles as all genotypes are 
represented in a certain regularity.   
 
Figure 21: Allele frequencies of only 3D7-type alleles. Frequencies > 5 % are indicated with 
exact allele frequency, with fragment length and allelic type. The green colour depicts 3D7-type 
alleles. Lengths of fragment are indicated in bp. 
In contrast, within the D10-type alleles, 77.01 % were represented by only four different 
genotypes. In particular, three genotypes with the following fragment size are 
overrepresented: 336 bp, 417 bp and 371 bp with 33.33 %, 20.69 % and 17.24 %, 
respectively. Figure 22 depicts this pattern by showing all 15 D10-type alleles and 
highlighting all genotypes with frequencies above 5 %. 
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3D7  254 bp 
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7.87 % 
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Figure 22: Allele frequencies of only D10-type alleles. Frequencies > 5 % are indicated with 
exact allele frequency, with fragment length and allelic type. The blue colour represents D10-
type alleles. Lengths of fragment are indicated in bp. 
In summary, 3D7-type alleles were more diverse than D10-type alleles. Certain D10-
type alleles, however, were represented in higher frequencies. To examine the 
distributions once more, I constructed Figure 23 and Figure 24. Figure 23 shows that 
3D7-type alleles have a slightly skewed distribution over a wide range of fragment 
lengths. In stark contrast, D10-type alleles (Fig. 24) exhibit a pronounced discrete 
distribution pattern – three alleles across the range of observed fragment lengths are 
clearly dominant. 
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D10 417 bp 
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17.24 % 
D10 407 bp 
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Figure 23: Fragment sizes and respective frequency of 3D7-type alleles. X-axis showing 
fragment size in bp, y-axis demonstrating the number of occurrences. 
 
Figure 24: Fragment sizes and respective frequency of D10-type alleles. X-axis showing 
fragment size in bp, y-axis demonstrating the number of occurrences. 
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Concluding the analysis of allele frequencies among baseline samples, it can be said 
that firstly, all genotypes that occurred > 5 % in the baseline population belonged to 
D10-type alleles and secondly, 3D7-type alleles were far more diverse than D10-type 
alleles.  
Certain genotypes, primarily D10 336 bp, is overrepresented 
D10 336 bp stands out due to its high representation of 16.48 %, but also certain other 
genotypes stand out due to their high allele frequency. Having detected this pattern, I 
wondered about the reasons of the overrepresented genotypes, especially D10 336 bp, 
and whether a bias might have occurred.  
Genotypes found in negative control  
While comparing the pie charts it stands out that the dataset from Bobo-Dioulasso has 
one prominent genotype: D10 336 bp. I checked all negative controls to understand 
whether the high appearance of this genotype could be explained by a contamination. 
The total of negative controls was 19. Six negative controls were inconspicuous, but 12 
out of 19 negative controls could not be examined successfully by CE; the GeneScan® 
software produced unreadable electropherograms. One negative control attracted 
attention because it was contaminated. Figure 25 shows an inconspicuous negative 
control, whereas Figure 26 illustrates the contaminated negative control.  
 
Figure 25: Inconspicuous negative control. X-axis shows length of detected PCR-fragments in 
bp. Y-axis depicts detected intensity in rfu. 
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Figure 26: Contaminated negative control. X-axis shows length of detected PCR-fragments in 
bp. Y-axis depicts detected intensity in rfu. 
To analyse whether this negative control had an outcome on my results, I arranged 
Table 17, which illustrates the genotypes that occurred in the contaminated negative 
control and shows how often these genotypes appeared in the baseline population and in 
recrudescences. The following PCR-fragments are represented above cut-off and were 
therefore interpreted as contaminations: 3D7 254 bp, D10 313 bp, D10 336 bp and 
D10 348 bp.  
Table 17 Genotypes detected in contaminated negative control and their frequency in the 
baseline population. 
 
 
 
 
 
 
 
Three out of four genotypes appeared in the baseline population in different frequencies.  
Repeating CE genotyping led to consisting results 
As an attempt to double-check whether the results that I gained during my laboratory 
work contained errors, a second analysis of the samples was undertaken two years after 
the first analysis. In the following, the first analysis that I conducted will be referred as 
Genotyping-2014 and the second analysis will be referred as Genotyping-2016.  
 Size (bp) Baseline population 
(%) 
3D7 254 3.98 
D10 313 0.57 
 336 16.48 
 348 - 
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In Genotyping-2016, only 44 of 126 samples (34.92 %) could be evaluated. Out of these 
44 samples, 28 samples showed identical genotypes and 16 samples revealed identical 
genotypes but additional genotypes in Genotyping-2014. 
These results from 2016 confirm the results from 2014 and therefore a contamination in 
the step of PCR or CE is unlikely. However, given that a new DNA extraction from 
filter paper blood samples was not consistently possible due to a lack of samples, 
Genotyping-2016 was conducted using previously extracted DNA from the laboratory 
work in 2014. It can thereby not be excluded that a contamination in the first step of 
genotyping, the DNA extraction, had occurred.  
For the reason of possible bias, I decided to exclude the genotypes from the 
contaminated negative control and to recalculate the allele frequencies. For all further 
calculations, the genotypes listed in Table 17 were excluded.   
Excluding genotypes 
By excluding all genotypes listed in Table 17, certain paired samples, which had only 
shown one of the genotypes from the contaminated negative control and no other 
genotypes, were excluded from further analysis.  
Out of 63 paired samples, 47 could be extracted and amplified. Two paired samples 
within the AL-arm were excluded due to stutter peaks. 16 paired samples could not be 
successfully extracted or amplified; three complete paired samples (2 AL, 1 DP) could 
not be examined as well as 13 single samples (12 AL, 1 DP). If a single sample could 
not be extracted and amplified successfully, the corresponding paired sample to which it 
belonged was excluded as for this analysis only fully paired samples were examined 
through CE genotyping. Thus, the sample size consisted of 37 paired samples for all 
further calculations (Fig. 27). I recalculated allele frequencies with all genotypes from 
these 37 sample pairs.  
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Figure 27: Positive and negative samples demonstrating amount of analysed and excluded 
samples. 
It can be seen in Figure 28 that after excluding the genotype D10 336, other D10 
genotypes are overrepresented. In spite of having excluded possibly biasing genotypes, 
D10 genotypes are represented in a small variable of genotypes, but in high allele 
frequencies, as could be shown before. 3D7 genotypes on the other hand are represented 
in a polymorphic pattern with frequencies of 5.61 % or lower. Figures 29 to 30 illustrate 
these findings. 
63 paired samples 
(=126 samples) 
47 positive paired samples 
(100 %)  
37 paired samples 
(78.72 %) 
2 excluded paired 
samples due to stutter 
peaks (4.26 %) 
8 excluded paired 
samples after 
exclusion of 
genotypes from 
negative control 
(17.02 %) 
16 negative paired samples 
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Figure 28: Allele frequency without excluded genotypes. Frequencies > 5 % are indicated with 
exact allele frequency, with fragment length and allelic type. The green colour depicts 3D7-type 
alleles and the blue colour represents D10-type alleles. Lengths of fragment are indicated in bp. 
 
Figure 29: Only 3D7-type alleles without excluded genotypes. Frequencies > 5 % are indicated 
with exact allele frequency, with fragment length and allelic type. The green colour depicts 
3D7-type alleles. Lengths of fragment are indicated in bp. 
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Figure 30: Only D10-type alleles without excluded genotypes. Frequencies > 5 % are indicated 
with exact allele frequency, with fragment length and allelic type. The blue colour represents 
D10-type alleles. Lengths of fragment are indicated as bp. 
3.4 Recurrences 
Recrudescences per treatment arms 
Given the low sample size and equally important, the uneven distribution of samples 
between study groups, I will use the limited available data for illustrating the power of 
precise genotyping for the interpretation of antimalarial drug trials.  
Out of 37 paired samples, 29 paired samples belonged to the AL-treatment arm, and 4 to 
the DP and the PA-treatment arm, respectively (Fig. 31).  
Figure 32 further depicts how many recurrences, meaning the sum of new infections 
and recrudescences, and how many recrudescences appeared in each treatment arm: 
seven recrudescences in the AL treatment arm and one recrudescence in the PA 
treatment arm. No recrudescence appeared in de DP treatment arm. The percentage of 
recrudescences in my small sample size was of 21.62 %. 24.14 % of samples from the 
AL treatment arm and 25 % of samples in the PA treatment arm showed 
recrudescences.  
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29.79 % 
D10 371 bp 
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Figure 31: Analysed samples. Distribution per treatment arm. 
 
Figure 32: Amount of recurrences (black), hence the sum of new infections and recrudescences, 
compared to amount of recrudescences (gray) distributed by allocated treatment arm. X-axis 
number of paired samples. Y-axis allocation to treatment arm. 
Analysing genotypes represented in recrudescences 
As I analysed allele frequencies in the previous chapter, I noticed that two genotypes in 
particular (D10 371 bp and D10 417 bp) were overrepresented in the baseline 
population. The next step was to examine whether these genotypes were 
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overrepresented within recrudescences as well. I constructed Figure 33 to examine the 
distribution of genotypes among recrudescences.  
Recrudescences appeared in 8 cases. Figure 33 underlines our findings from above: 
Fewer D10 genotypes are highly represented, and 3D7 is represented in a higher variety. 
For D10 genotypes, the two genotypes with the highest allele frequencies in the baseline 
population (D10 417 bp with 13.08 % and D10 371 bp with 11.22 %) are represented 
with two (25 %) recrudescences each. In the baseline population, the four 3D7 
genotypes, which are responsible for recrudescences, are represented with a frequency 
of 1.87 % (3D7 326 bp) and 3.74 % (3D7 242 bp, 3D7 264 bp, 3D7 276 bp). In 
recrudescences they hold a frequency of 12.5 %. Even though other 3D7 genotypes are 
represented in the baseline population with up to 5.61 % (3D7 272 bp), the latter are not 
proportionally represented in recrudescences. This means, that not only the frequency in 
the baseline population has an impact on its representation in recrudescences. It should 
be concerned that certain genotypes hold more dominance than others. It has to be said, 
though, that the data represented in this thesis is limited due to its small sample size and 
uneven distribution between treatment arms. Further analyses from a bigger sample size 
have to be awaited before drawing conclusions.  
 
 
 D10 371 bp  
25 % 
D10 417 bp   
25 % 
3D7 242 bp 
12.50 % 
3D7 264 bp 
12.50 % 
3D7 276 bp 
12.50 % 
3D7 326 bp 
12.50 % 
Figure 33: Genotypes in recrudescences. The genotypes are depicted in their respective 
frequencies and fragment length. Green colour represents 3D7-type alleles and blue 
colour depicts D10-type alleles. Lengths of fragment are indicated as bp. 
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3.5 MOI, P and heterozygosity of infection 
Risk of falsely classified recrudescence due to high frequency 
A misclassification as a recrudescence may occur, when in reality the recurrence is 
caused by a second infection with the same genotype. I calculated the probability of 
being infected twice by two different parasites with an identical genotype. I did this by 
putting the frequency in the baseline population by the power of two. It becomes clear 
that even in genotypes, which appeared in a high allele frequency in the studied dataset, 
the probability of being infected by two parasites with the same genotype is very low 
and thus, it is unlikely that a recurrence showing a recrudescence derives from a second 
infection with the same genotype. I constructed Table 18 to demonstrate the frequency 
of recrudescent genotypes and to compare it to the frequency in the baseline population. 
Furthermore, it depicts the probability of being infected twice by a parasite with an 
identical genotype for all genotypes that occurred in recrudescences. Even genotypes 
with a frequency of 25 % in recrudescences showed only a probability of 1.26 % of a 
second infection with a parasite holding the same genotype. This source of bias can 
therefore be neglected for the examined population. 
Table 18 Genotypes in recrudescences. Their frequency in the baseline population and in 
recrudescences. Moreover, the probability of being infected by two parasites with the same 
genotype for each genotype. 
Genotype Allele frequency in 
baseline population 
Frequency in 
recrudescence 
Probability of 
being infected by 
two parasites with 
same genotype 
D10 371 bp 0.1122 0.25 0.0126  
D10 417 bp 0.1308 0.25 0.0171 
3D7 242 bp 0.0374 0.125 0.0014 
3D7 264 bp 0.0374 0.125 0.0014 
3D7 276 bp 0.0374 0.125 0.0014 
3D7 326 bp 0.0187 0.125 0.0003 
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MOI and HE correspond to expected values in a high transmission area  
High allele frequencies in an investigated population can be the cause for 
misclassification of recrudescences: when certain allele frequencies are very high, the 
probability increases of being re-infected by chance a second time with the same 
genotype. This would lead to misclassifications as recrudescences when in reality it is a 
new infection with the same genotype. CE genotyping cannot distinguish between this 
incidence and a real recrudescence, but the below specified parameters formulate an 
approach to understand the probability of real recrudescences. Furthermore, they are a 
measure for genetic diversity of the population as much as a possability to assess the 
discriminatory power of the msp-2 marker. The formulas for MOI, P and for HE are 
specified in chapter 2.2.12. 
The MOI is an indicator for the transmission intensity in an examined population. High 
MOI is typical for high transmission areas and implies than an infection is likely to be 
caused by more than one genotype. In this thesis the MOI was calculated as 
MOI = 2.89.  
The theoretical probability P of being re-infected a second time by an identical genotype 
is calculated to understand whether the marker gene used for CE genotyping is 
polymorphic enough for showing adequate discrimination power. In this thesis, msp-2 
was chosen as marker gene as it is known for its polymorphic nature. P stands for the 
theoretical probability of being infected two times by two different parasites sharing the 
same genotype. For this dataset, I calculated P = 0.0486.  
HE was calculated to understand the probability that two alleles, which were randomly 
selected from all samples, are different. HE is defined as the probability of two 
randomly selected genotypes are different in the population and was calculated as 
HE = 0.978 for the study at hand.  
3.6 Summary 
I calculated allele frequencies and recrudescences. Analysing my results demonstrated 
several findings on characteristics of 3D7-type alleles compared to D10-type alleles. 
3D7-type alleles occur with a higher polymorphism, but D10-type alleles occur in 
Results 
 
 
52 
higher frequencies, both in the baseline population and in recrudescences. I calculated 
recrudescence rates per treatment arm and analysed allele frequencies in 
recrudescences. It was confirmed in recrudescences, that 3D7 showed a higher 
polymorphism and that D10 was represented in a fewer number but each genotype in a 
higher frequency. Last, I calculated approaches to understand the probability of falsely 
classified recrudescences and to measure the genetic diversity of the studied population.  
The question remains why D10-type alleles often appear in high allele frequencies and 
why certain genotypes are overrepresented. To be able to understand whether results 
from the present study are compatible with findings from unpublished and published 
data, I analysed and compared them with my results in the following chapter. 
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4  Discussion 
Genotyping has become an important tool to assess PCR-corrected treatment failure 
rates in antimalarial drug trials and therefore to investigate resistances. I conducted a 
study implementing a genotyping protocol with CE with an automated sequencer and 
analysed my samples regarding recrudescence rates and allele frequencies. 
Below, I will start discussing technical limitations of the methods and limitations of 
genotyping due to the malaria parasite’s biology. I will then put my results in a broader 
context and compare my results with published data and with two datasets from the 
CATMAP-trial, which took place in Kilifi. Finally, I will close with future prospects 
and conclusions drawn from my study. 
4.1 Technical limitations  
Each step of genotyping holds certain limitations. In the following I will discuss the 
limitations that I encountered during my analyses. 
DNA extraction 
DNA was extracted from blood samples on untreated Whatman™ 3MM collection 
cards even though untreated filter papers do not protect from degradation of nucleases, 
oxidation, UV damage or microbial fungal growth and should be avoided for the 
purpose of genotyping (World Health Organization 2008). Instead, treated collection 
cards that guarantee a high quality of DNA storage should be used (Felger & Snounou 
2008). However, untreated collection cards are available at low cost and are therefore 
frequently used in field studies.  
The volume of blood size is crucial when it comes to genotyping; too small volumes 
may result in a negative result in spite of peripheral parasitaemia. However, collecting 
blood samples on filter papers leads to non-standardized blood volumes and it is 
difficult to estimate the amount of blood on the collection cards. Within the samples for 
this study the amount of blood on the filter paper varied visibly. 
DNA extraction was not performed with a commercial extraction kit but using the 
methanol method. As could be shown in this study by conducting two PCRs using the 
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same extracted DNA two years apart this method may not allow a long-term storage of 
extracted DNA. In Genotyping-2014, the amplification was conducted within a few 
days after extraction of DNA and was successful in 74.60 %. For Genotyping-2016, the 
same extracted DNA was taken two years later and only 34.92 % of samples could be 
successfully amplified. Moreover, 28 samples showed additional genotypes in 
Genotyping-2014 compared to Genotyping-2016 indicating that DNA may have 
denatured in the mean time. A review by Collins et al. (2006) states that only 1 % of the 
analysed studies used the methanol method to extract DNA and rather suggests using 
the Chelex method if not extraction kits. 
PCR 
A typical problem of PCR is a defective Taq-polymerase. This may happen due to 
frequent freeze thawing (Felger & Snounou 2008) or when Taq-polymerase loses its 
activity before the reaction should start because it has thawed too early. To prevent this, 
on the one hand I portioned the Taq-polymerase into small aliquots to avoid frequent 
freeze thawing of each aliquot. On the other hand I worked on an iced tablet and 
pipetted the Taq-polymerase as last agent into the mastermix to prevent early onset of 
loss of activity. 
Moreover, using the fitting primer is essential to have a productive outcome. The M5 
and N5 primers for the sPCR are marked by a fluorescent tail, which loses its 
fluorescent activity when it encounters light. To prevent the loss of fluorescent activity, 
M5 and N5 were stored in opaque reservoirs. 
Due to several biological reasons, which will be discussed subsequently, P. falciparum 
DNA may be represented in small quantities in the patient’s blood stream. If the amount 
of P. falciparum DNA is very low, it may fall underneath the detection limit and can 
therefore not be examined using genotyping. Genotyping may therefore not reflect the 
true amount of possible coexisting infections, which may lead to a misclassification of a 
recurrence and therefore should be considered as possible source of error.  
Positive and negative controls are crucial tools to make a statement about the credibility 
of a study, as PCR is susceptible for contamination. In the present study, a 
P. falciparum negative human DNA control was not established despite the suggestion 
by World Health Organization (2008). I introduced negative controls in each step of 
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genotyping and added positive controls for both allelic families. In 12 cases, negative 
controls were not interpretable by the GeneScan® software and could therefore not be 
depicted as electropherograms. To assure that no contamination has taken place, it 
would be of importance to be able to read the data of these not interpretable negative 
controls, which means that in this case it would have been appropriate to repeat the 
analyses on these samples. Moreover, one negative control was contaminated with four 
genotypes, which led to an exclusion of these genotypes and repeated calculation of 
allele frequencies to exclude the bias of contamination. A second genotyping procedure 
was conducted with the same samples that led to consisting results and confirms that no 
relevant contamination had appeared in during PCR. However, given that a new DNA 
extraction from filter paper blood samples was not consistently possible due to a lack of 
samples, Genotyping-2016 was conducted using previously extracted DNA from the 
laboratory work in 2014. It can thereby not be fully excluded that a contamination had 
occurred in the first step of genotyping, in the DNA extraction.  
Interpretation of electropherograms 
One disadvantage of CE genotyping is the interpretation of electropherograms; to be 
able to read electropherograms, it is of fundamental importance to determine a cut-off 
that defines which peaks to count as genotypes. The cut-off in the present study was 
defined as 0.1 rfu of the highest peak in each electropherogram as shown by Messerli et 
al. (2016). Other work groups have defined the cut-off differently: Choosing the cut-off 
at 300 rfu as shown by Liljander et al. (2009) brings the drawback of misinterpreting 
electropherograms. In my study, I could show that this method results in defective 
findings: I compared Genotyping-2014 and Genotyping-2016 and saw that in 16 cases, 
peaks < 300 rfu in Genotyping-2016 appeared as clear peaks above 300 rfu in 
Genotyping-2014. This implies that these peaks did derive from real msp-2 fragments, 
but that other factors caused smaller peaks underneath 300 rfu in Genotyping-2016.  
A different method to define the cut-off is described by Falk et al. (2006), who used an 
in-house generated software to identify each peak by sample-specific evaluation. Not 
having had this possibility, I chose to determine the cut-off as described above. This 
method gives the possibility to consider sample-specific effects and therefore 
guarantees a higher standard. 
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Another difficulty in the interpretation of electropherograms is the appearance of 
artefacts such as inherent fluorescent background, which usually shows peaks below 
50 rfu (Liljander et al. 2009) and can therefore easily be excluded. Stutter peaks on the 
other hand appear as an artefact that is explained by slipped strand mispairing (Walsh et 
al. 1996). Stutter peaks are characterized by regular peaks approximately every 20 bp 
and an intensity that is often represented by < 10 % of the highest peak in the 
electropherogram (Liljander et al. 2009). The example shown in Figure 34, which can 
be seen in the appendix, shows stutter peaks with gaps of 16 – 19 bp. Because of the 
difficulty of understanding with certainty whether a peak belongs to a genotype or to the 
stutter peak, two samples showing stutter peaks were excluded from analysis in this 
study.   
Genetic markers 
In the study at hand I introduced a protocol for msp-2 genotyping to samples from the 
WANECAM-trial. Before classifying a sample as a recrudescence, several steps of 
genotyping have to be completed: According to World Health Organization (2008) a 
recrudescence that was defined after having conducted genotyping with msp-2 markers 
has to be reinvestigated by using the GLURP marker. If genotyping with GLURP still 
indicates a recrudescence, msp-1 should be analysed. Only now, after having examined 
all three markers consecutively and after having detected a recrudescence in all three 
procedures, a sample can be defined as a recrudescence.  
Given that for the present study only msp-2 was analysed, samples that were labelled as 
recrudescences should be examined with the GLURP marker and if needed with the 
msp-1 marker. The results of this study can therefore not lead to the assumption that the 
efficacy of the examined drugs is impaired before further analyses. 
4.2 Biological aspects 
Several biological aspects of the P. falciparum life cycle have to be considered when 
critically evaluating P. falciparum genotyping. These aspects include the late 
appearance of gametocytes long after the disappearance of asexual blood stages from 
the blood stream, but also the characteristics of the P. falciparum life cycle in the 
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human host. In addition, I will discuss certain aspects of transmission dynamics 
between the human and the anopheline host.  
Gametocytes 
Gametocytes derive from asexual blood stages and become detectable in the peripheral 
blood stream 7 – 15 days after the appearance of the latter (Bousema & Drakeley 2011). 
If gametocytes occur on the day of recurrence they may become a source of 
misclassification: samples containing gametocytes on the day of recurrence may 
mistakenly be interpreted as a recrudescence (Snounou & Beck 1998)(Felger & 
Snounou 2008). Within the samples used in this thesis, none showed appearance of 
gametocytes under microscopy on the day of recurrence. It cannot be excluded, though, 
that patients had microscopically undetected gametocytaemia on their day of recurrence. 
Asynchronity and sequestration 
A single inoculation of an Anopheles mosquito may cause multiple infections. 
P. falciparum parasites take seven to 25 days to develop into their clinically apparent 
stages showing peripheral parasitaemia (Snounou & Beck 1998). Hence, one 
inoculation may cause parasitaemia in different time points due to a co-infection of 
parasites. 
The peripheral detectability of P. falciparum follows a 48-hour periodicity as a 
consequence of the parasite’s life cycle. Late erythrocytic stages sequester into deep 
tissues and capillaries by cytoadherence to endothelial receptors and are not necessarily 
detectable in the peripheral blood stream during this time (Falk et al. 2006). Genotyping 
samples from asymptomatic children over a long-term period has demonstrated that 
genotypes vary on a daily basis showing different parasites on consecutive days (Farnert 
et al. 1997). This could also be underlined by Jafari et al. (2004) and Missinou et al. 
(2004) who both analysed multiple samples within the first days after administration of 
the drug. They found that genotypes disappeared and reappeared after a certain time 
period. This might be explained by varying capillary adhesion characteristics of certain 
parasites (Jafari et al. 2004).  
The two pathomechanisms described above lead to the conclusion that parasites, which 
have not yet developed into their asexual blood stage or are sequestered, may be 
overlooked by taking a single blood sample. The consequence is of misclassifying the 
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sample as a new infection despite it being a co-infection from day 0. A solution to 
determine a less faulty statement on the true amount of genotypes deriving from the 
same inoculation could be the examination of multiple samples as suggested by 
Martensson et al. (2007):  By taking multiple blood samples within 0 – 3 days after drug 
administration, 32 additional genotypes could be found in 25 % of patients. Moreover, 
18 % of recrudescences were identified only when examining multiple samples. Thus, it 
may be of interest to enhance a protocol including multiple blood samples after 
treatment to cover a broader variety of genotypes during the baseline infection on day 0 
and therefore being more certain that recurrences are not misclassified. On the other 
hand, World Health Organization (2008) advises against taking multiple blood samples 
on consecutive days as it adds costs, possible errors and requires extensive statistical 
evaluation. 
Transmission dynamics 
Even though using ITNs is highly recommended in malaria endemic areas, a survey 
showed that only 66 % of the interviewed people in Burkina Faso had slept underneath 
an ITN in the previous night (World Health Organization 2016).  
The patients investigated in the present study were treated at the local dispensary and 
then discharged. As Anopheles mosquitoes live for up to 30 days (CDC 2017f), the 
Anopheles mosquito that infected a patient the first time might easily re-infect the 
patient after the drug’s activity has diminished. Moreover, the Anopheles mosquito 
might have infected other members of the same family. Hence, different Anopheles 
mosquitoes in the same household can acquire a similar mixture of genotypes because 
they feed on the same people within one house. They can thus transmit the same 
population of parasites (Snounou & Beck 1998). Moreover, if the investigated 
population lives in a small area, this population shares a similar gene pool of malaria 
parasites. The leading clinical physician of the study site in Bobo-Dioulasso estimated 
that patients who were enrolled in the study lived zero to four kilometers away from the 
study site. The proximity of the investigated patients could explain why certain 
genotypes occurred in high frequencies.   
A paired sample showing the same genotype is defined as a recrudescence. In addition 
to the previously explained mechanisms, a misclassification as a recrudescence could 
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also occur due to high allele frequencies of certain genotypes: by chance, a person can 
be infected twice with the same genotype. However, this re-infection with 
coincidentally the same genotype cannot be differentiated from a recrudescence by CE 
genotyping. Mathematical parameters P and HE may help to estimate the possibility of 
this happening. To gauge the theoretical probability of being infected twice by different 
parasites with the same genotype, P can be calculated as explained previously. The 
heterozygosity of infection (HE) can be calculated to estimate the probability within one 
population that two samples contain the same genotype.  
CE genotyping is an excellent method to investigate PCR-corrected treatment failure 
rates. However, several above mentioned reasons might lead to misclassifications of 
infections. It may therefore be indicated to employ more complex statistical models, 
which estimate more accurately how likely misclassifications are (Falk et al. 2006) 
(World Health Organization 2008). 
4.3 Results of the present study in a broader context 
I compared the dataset investigated in this study with similar data from the CATMAP-
trial that was conducted in Kilifi, Kenya. The data, which was gained through high-
resolution msp-2 CE genotyping comprised fragment sizes and allele-types from paired 
samples of patients, who had suffered a recurrence of uncomplicated P. falciparum 
malaria. I named the datasets Kilifi-1 and Kilifi-2. I binned the genotypes into 3 bp bins 
and calculated allele frequencies and recrudescence rates. Moreover, I discussed the 
results from the present study by comparing them with published genotyping data. 
3D7 shows higher polymorphism than D10 
Most genotypes being represented > 5 % belonged to the D10-family. However, the 
polymorphism of genotypes is bigger within the 3D7-family, which leads to a balanced 
representation of each approximately 50 % of D10-type alleles and 3D7-type alleles. 
Table 22 and Figures 35 – 36 in the appendix demonstrate the number of different 
genotypes in Bobo-Dioulasso and in Kilifi as well as the distribution of infections 
between 3D7-type alleles and D10-type alleles. It can be seen that Bobo-Dioulasso 
showed the smallest number of different genotypes with 44 genotypes (30 3D7 and 14 
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D10), whereas Kilifi-1 showed 172 different genotypes (97 3D7 and 75 D10) and Kilifi-
2 showed 74 different genotypes (42 3D7 and 32 D10). 
A broad variety of genotypes was documented in several published papers; Mwingira et 
al. (2011) found a variety of 116 (83 3D7 and 33 FC27) different msp-2 genotypes at 
five study sites, of which the study site in Burkina Faso demonstrated 71 genotypes for 
3D7 and 26 genotypes for D10. Falk et al. (2006) found a variety of 164 different msp-2 
genotypes in Ghana (116 3D7 and 48 FC27) and Schoepflin et al. (2009) who compared 
a high transmission area in Tanzania with a low transmission area in Papua New Guinea 
found 76 and 35 different msp-2 genotypes, respectively (59 3D7 and 17 D10 in 
Tanzania, 27 3D7 and 8 D10 in Papua New Guinea).  
Interestingly, 3D7 showed consistently a broader polymorphism than D10 in all of the 
analysed datasets and in the published data. A second interesting fact is that the 
investigated samples from Bobo-Dioulasso showed lower polymorphism that the 
compared data. A reason to explain this could be the small sample size of n = 37. Kilifi-
1 and the published studies analysed bigger sample sizes above 100 samples. On the 
other hand, Kilifi-2 showed nearly twice as many genotypes than Bobo-Dioulasso with 
a similar sample size of n = 47. Thus, the sample size cannot be the only factor 
determining the polymorphism of msp-2. Other factors such as transmission intensity 
have to be taken into consideration. 
Identical genotypes are overrepresented  
Certain genotypes occur in high frequencies in Bobo-Dioulasso, in Kilifi and also in 
published data examining samples from Burkina Faso. Table 22 in the appendix 
demonstrates a comparison between the genotypes in Bobo-Dioulasso and in Kilifi, 
which are overrepresented with an allele frequency > 3 %. Before exclusion of this 
genotype, D10 336 bp was the genotype with the highest frequency of 16.42 % in Bobo-
Dioulasso. It was as high as 5.33 % in the Kilifi-1 and of 4.36 % in the Kilifi-2 cohort. 
Results from Mwingira et al. (2011), who examined samples from Burkina Faso using 
CE genotyping, confirmed these findings. Mwingira and coworkers published that 
within their examined population the genotype D10 336 bp held the highest allele 
frequency with 9 % in Burkina Faso. The exclusion of D10 336 bp was necessary in this 
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thesis due to possible bias. It can be shown, though, that it is known to be a genotype, 
which appears in a high frequency in Burkina Faso and in Kilifi.  
After exclusion of D10 336 bp, the two genotypes with the highest allele frequencies 
were D10 417 bp with 13.08 % and D10 371 bp with 11.22 %. In the Kilifi-1 dataset, 
D10 371 bp was the most prominent genotype with a frequency of 6.53 %. The study of 
Mwingira et al. (2011) underlines these findings as they found, that these genotypes 
were represented within the three most frequent genotypes with an allele frequency of 
4 % for D10 417 bp and D10 371 bp, respectively. 
Published data from different locations found similarly high allele frequencies within 
their examined populations: Falk et al. (2006) published that the genotype with the 
highest allele frequency was of 14 % and Schoepflin et al. (2009) of 11.2 %. 
Remarkably, the analyses did show that first, each population contains prominent 
genotypes and that second, these prominent genotypes belong to the D10-family. To 
understand if identical genotypes occurred in high allele frequencies in Bobo-Dioulasso 
as well as in the Kilifi datasets I constructed Table 22 that can be seen in the appendix. 
The table illustrates that despite the immense distance between the study sites at which 
the samples were collected, most prominent genotypes in Bobo-Dioulasso could also be 
detected among the most frequent genotypes in the Kilifi-datasets. This may suggest 
that certain genotypes stand under less selection pressure and therefore thrive over big 
parts of the African continent. 
D10-type alleles cause most recrudescences 
The results of the Kilifi-datasets demonstrated that most recrudescences were caused by 
D10-type alleles. In Bobo-Dioulasso, D10-type alleles were responsible for 50 % of 
recrudescences. The Kilifi-1 dataset revealed that 75.67 % of recrudescences occurred 
due to D10-type alleles, of which six genotypes showed a recrudescence rate of > 5 % 
and were responsible for 62.17 % of all recrudescences. Figures 37 – 38 in the appendix 
show the allele frequencies within recrudescences in Kilifi-1 and Kilifi-2. The Kilifi-2 
data showed that 83.31 % of recrudescences occurred due to D10-type alleles.  
In spite of the geographical distance between Bobo-Dioulasso and Kilifi, analyses 
between these cohorts showed that D10-type alleles were clearly overrepresented in 
both Kilifi cohorts and the Bobo-Dioulasso cohort. Moreover, D10-type alleles were 
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likely to be responsible for more than one recrudescence each. This leads to the question 
whether certain D10-type genotypes are more dominant than others and whether they 
somehow are more likely to provoke recrudescences than 3D7-type alleles.  
Looking at the three datasets, it stands out that there are always overrepresented 
genotypes responsible for recrudescences. In Bobo-Dioulasso, it is D10 371 bp and 
D10 417 bp, which are responsible for 50 % of recrudescences. In Kilifi-1 it is 
D10 371 bp that is responsible for 18.92 % of recrudescences and in Kilif-2 it is 
D10 264 bp that is responsible for 25 % of recrudescences. All most prominent 
recrudescences are caused by a D10-type allele. To track down whether the genotypes 
found in recrudescences are in proportion to their population I constructed Tables 23 – 
24 for Kilifi-1 and Kilifi-2, which can be seen in the appendix. It stands out that 
genotypes responsible for recrudescences were not always in proportion with their 
frequency in the baseline population.  
Falk et al. (2006) analysed the duration of infections and showed that turnover rates for 
3D7 were higher than for FC27 (D10) genotypes and stated that this may indicate that 
FC27 genotypes are more robust against being eliminated through the host’s immune 
system. Even though the duration of infections was not explicitly determined, the results 
in the study at hand confirm such a hypothesis as most genotypes that were represented 
in a high frequency belonged to the D10-family and were not necessarily in proportion 
with their appearance at baseline. The higher frequency of D10 genotypes in 
recrudescences might suggest that infections with D10-type alleles bring a higher risk of 
recrudescence. Further analyses on a bigger sample size should be awaited to confirm 
this hypothesis. 
Recrudescence rates 
The recrudescence rates of the study at hand with 21.62 % recrudescences in total and 
of 25 % in samples of the AL- and the PA-treatment arm are alarmingly high. World 
Health Organization (2008) recommends retesting when the PCR-corrected treatment 
failure rate exceeds 10 % or the MOI passes four. However, the study at hand was 
conducted with a small sample size that does not allow conclusions concerning the 
treatment failure rates or the efficacy. The transferability of the results is especially 
limited for samples from patients who were treated with DP or PA as the samples sizes 
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consisted of four paired samples, respectively. To gain statistically relevant results I 
highly recommend examining a larger sample size of patients that were enrolled in the 
WANECAM-trial in Bobo-Dioulasso. This will lead to a more valuable statement about 
PCR-corrected treatment failure rates of AL, DP and PA in Bobo-Dioulasso. Also, 
results from other study sites of the WANECAM-trial both concerning recrudescence 
rates and allele frequencies should be compared to gain further information about allele 
frequencies in different settings in Western Africa.  
Ultimately, when allele frequencies for certain genotypes are high, samples can 
incorrectly be classified as recrudescences even though the cause for the recurrence is a 
new infection with a parasite holding the same msp-2 genotype as the parasite infecting 
the patient the first time. Reasons for this misclassification are explained in preceding 
chapters. Putting alleles, which appeared in a high frequency in the power of two is a 
possibility of calculating the risk of falsely classifying new infections as 
recrudescences. It could be shown that this possibility of incorrectly misclassifying 
recrudescences is negligibly low for the examined population. 
MOI, P and HE 
The MOI is dependent from the transmission intensity. High transmission areas are 
likely to show a higher MOI than low transmission areas. The results form this study 
with a MOI = 2.89 correspond to the observation that MOI increases in high 
transmission areas compared to low transmission areas (Schoepflin et al. 2009).  
Comparable data from Mwingira et al. (2011) found a MOI of 3.03 in Burkina Faso and 
Schoepflin et al. (2009) showed and MOI of 3.72 in Tanzania, which underline the 
findings from this study. The MOI in a low transmission area on the other hand is 
reflected exemplary by an MOI of 1.84 in Papua New Guinea (Schoepflin et al. 2009).  
Another important factor is the theoretical probability P of being infected twice with an 
identical genotype. The probability of two infections randomly being caused by the 
same genotype decreases when the polymorphisms for the investigated marker gene is 
high (Snounou & Beck 1998). Values of P < 0.05 indicate a low probability of being re-
infected with the same genotype by two different parasites (Gatton & Cheng 2008). 
Therefore, the result from the study at hand with P = 0.0486 reflects that it is not likely 
to be infected twice by a parasite with the same genotype. The heterozygosity of 
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infection was calculated to understand the risk of two randomly picked samples 
carrying a parasite with the same genotype. The result of HE = 0.978 indicates it to be 
very likely to chose two different genotypes when randomly choosing from the 
population and therefore stands for a high expected heterozygosity within the examined 
population. Comparable data by Schoepflin et al. (2009) found HE = 0.965 in a trial 
which was conducted in Tanzania and HE = 0.933 in a trial conducted in Papua New 
Guinea. Especially the HE found in Tanzania is comparable to with the HE found in the 
study at hand, indicating a similar broad diversity of genotypes in these populations. 
This data suggests that for the examined population, analysing only msp-2 is sufficient 
as it shows a high discriminatory power. It has to be repeated, though, that due to the 
small sample size there may be a bias and therefore studies with greater sample size 
have to be undertaken to assure that examining only msp-2 is sufficient for valid results 
in the examined area. 
4.4 Conclusion and Outlook 
The present study demonstrates that CE genotyping was well established at the AG 
Borrmann laboratory at Eberhard Karls Universität Tübingen. Moreover, it was 
illustrated that it is an excellent method to determine recrudescence rates and allele 
frequencies of P. falciparum infections.  
The results from the present study demonstrate high recrudescence rates for two of the 
three tested treatments with a recrudescence rate of 25 % for both AL and PA. Looking 
at these results, it appears that these treatments should be further investigated as World 
Health Organization (2008) recommends retesting when the recrudescence rates exceed 
10 %. However, the study at hand was conducted with a small sample size of four for 
DP and PA and of 29 for AL. The transferability of the results is therefore limited and 
does not allow conclusions concerning the treatment failure rates nor the efficacy, as the 
results are not statistically valid. To be able to make a statement about the efficacy of 
AL, DP and PA in Bobo-Dioulasso, further analyses on a larger sample size have to be 
awaited. Also, results from the other study sites of the WANECAM-trial concerning 
both allele frequencies and recrudescence rates should be compared to obtain valuable 
information for all three countries. 
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Even though CE genotyping brings up the previously discussed problems, it still 
represents the favoured method for P. falciparum genotyping. Overall, high resolution 
CE genotyping remains an excellent tool to determine the characterization of the allele-
type and exact fragment length. It shows an advantage towards gel electrophoresis 
thanks to the improved sensitivity and specificity (Liljander et al. 2009) and has been 
recommended by World Health Organization (2008) instead of formerly performed gel 
electrophoresis as it shows a higher discriminatory power especially in high 
transmission areas. In addition, it provides exact information about parasite populations, 
multiplicity of infection and frequency distributions in different endemic settings. In the 
present study, the high reproducibility could be confirmed as results from two different 
PCRs showed identical results. High resolution CE should also be implemented in 
developing countries, for example by sharing facilities (World Health Organization 
2008). This would accelerate the process of genotyping and results could therefore be 
interpreted faster.  
Investigating more on parasite populations and allele frequencies in different endemic 
settings would lead to a broader understanding of true recrudescences and allele 
frequencies and therefore give more valuable information about treatment failures and 
thus efficacy of drugs. A goal could be the establishment of a map of allele frequencies 
throughout malaria endemic areas. By observing changes of allele frequencies a further 
understanding of the dynamics of different allelic families could be obtained. This could 
lead to a better understanding of transmission of genotypes. Moreover, a possible 
dominancy of allelic families or certain genotypes could be observed concerning both 
allele frequencies and recrudescences.  
Summary 
 
 
66 
5 Summary 
In the context of my dissertation I worked for nine months in Bobo-Dioulasso, Burkina 
Faso, as part of the WANECAM-trial, which compared the antimalarial agents 
dihydroartemisinin-piperaquine and pyronaridine-artesunate with the comparator drug 
artemether-lumefantrine. 
The aim of this pilot study was to implement P. falciparum merozoite surface protein 2 
genotyping using high-resolution capillary electrophoresis genotyping with an 
automated sequencer at the AG Borrmann laboratory at the Institute of Tropical 
Medicine of Eberhard Karls Universität Tübingen. I analysed if recurrences were caused 
by new infections or recrudescences. Furthermore, I determined allele frequencies and 
recrudescence rates of the studied population.  
In paired filter paper blood samples from patients from Bobo-Dioulasso, I extracted 
Plasmodium falciparum DNA, amplified it with a primary polymerase chain reaction 
and subsequently with a secondary polymerase chain reaction. I analysed the 
amplification products first by gel electrophoresis and second, using capillary 
electrophoresis with an automated sequencer. The software GeneScan® evaluated the 
results and presented them as electropherograms, which I interpreted and analysed. 
Of the 63 paired samples, I was able to extract and analyse 37 successfully. I noticed 
that 3D7-type alleles appeared in higher polymorphisms than D10-type alleles, but that 
D10-type alleles were responsible for high allele frequencies. I calculated a 
recrudescence rate of 21.62 % in total. Genotypes from the D10 family, which were 
highly represented in the baseline population, were also highly represented in 
recrudescences. For the 3D7 family, a similar proportionality could not be found. The 
recrudescence rates for artemether-lumefantrine and pyronaridine-artesunate were high 
with 25 % each. Further analyses with a bigger sample size as well as equal distribution 
between treatment arms should be awaitened before drawing further conclusions. 
The discussion of this study is subdivided into three parts: technical limitations of the 
methodology, biological aspects of P. falciparum and the comparison of my results with 
published and unpublished data. The technical limitations concerned mostly the 
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detection limit of P. falciparum when examined by CE genotyping. The biological 
aspects of the parasite’s life cycle, which cause difficulties with CE genotyping are 
firstly, that infections might be misclassified as recrudescences due to occurrence of 
gametocytes on the day of recurrence and secondly, that P. falciparum sequesters into 
deep tissues and is therefore not always detectable in the blood stream. This can result 
in certain genotypes not being detected on day 0 even though they have already spread 
in the human body. A misclassification as a recrudescence may also occur when, by 
coincidence, patients are re-infected by parasites with the same genotype. Furthermore, 
I compared my data with published and unpublished data and understood that the results 
were often consistent with each other: My results as well as the compared results show 
that firstly, 3D7-type alleles have a higher polymorphism than D10-type alleles, and 
that secondly each population has certain genotypes that are overrepresented and which 
tend to belong to D10 genotypes. 
The results of this study have shown that CE genotyping was well established for 
samples from Burkina Faso. The high recrudescence rates in this study are not 
statistically valid due to small sample size and due to unequal number per treatment 
arm. Further analyses of the WANECAM-trial should be awaited to draw conclusions 
concerning the efficacy of the examined drugs. The potential dominance of possible of 
certain genotypes in parasite populations should be monitored in malaria trials to 
prevent misinterpretation of genotyping results. 
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6 Zusammenfassung 
Für meine Dissertation arbeitete ich neun Monate lang im Rahmen der WANECAM-
Studie, in welcher Dihydroartemisinin-Piperaquin und Pyronaridin-Artesunat mit dem 
Kontrollmedikament Artemether-Lumefantrin verglichen wurden, in Bobo-Dioulasso in 
Burkina Faso.  
Die Fragestellung meiner Promotionsarbeit betraf die Einrichtung der Genotypisierung 
des Merozoiten Oberflächenproteins 2 von Plasmodium falciparum mit Hilfe der high-
resolution Kapillarelektrophorese, welche mit einem automatisierten Sequenziergerät im 
Labor der AG Borrmann des Instituts für Tropenmedizin, Reisemedizin, 
Humanparasitologie der Eberhard Karls Universität Tübingen durchgeführt wurde. Ich 
untersuchte Probenpaare auf Häufigkeiten der Allele in der Population sowie darauf, ob 
eine Wiedererkrankung auf eine erneute Infektion oder auf eine Rekrudeszenz 
zurückzuführen war.  
Ich extrahierte im Tübinger Labor die Plasmodium falciparum DNA aus 
Filterpapierproben aus Bobo-Dioulasso, amplifizierte diese mit Hilfe einer primären 
und einer sekundären Polymerase-Kettenreaktion und untersuchte das 
Amplifikationsprodukt vorerst mittels Agarose-Gelelektrophorese und bei erfolgreicher 
Extraktion im zweiten Schritt anhand der Kapillarelektrophorese im automatisierten 
Sequenziergerät.  
Von den 63 gepaarten Filterpapierproben konnte ich 37 Paare erfolgreich auswerten. 
Auffällig war zum einen der höhere Polymorphismus von 3D7 gegenüber D10. Zum 
anderen zeigte sich, dass einige Genotypen der D10-Familie in einer kleineren Varianz, 
jedoch jeweils in einer hohen Allelfrequenz auftraten. Es zeigte sich eine Rekrudeszenz-
Rate von insgesamt 21.62 %, wobei die Genotypen der D10-Familie, welche am 
häufigsten in der Population auftraten, auch am häufigsten bei den Rekrudeszenzen 
vertreten waren. Für Allele der 3D7-Familie zeigte sich diese Proportionalität nicht. Die 
Rekrudeszenzraten für Artemether-Lumefantrin und Pyronaridin-Artesunat waren 
besonders hoch mit jeweils 25  %, jedoch sollten weitere Analysen mit einer höheren 
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Probenanzahl sowie gleichmäßiger Verteilung der Proben zwischen den drei 
Studienarmen abgewartet werden. 
In der Diskussion dieser Arbeit ging ich auf die technischen Einschränkungen der 
Methodik, die biologischen Aspekte von Plasmodium falciparum sowie den Vergleich 
meiner Ergebnisse mit veröffentlichten und unveröffentlichten Daten ein. Die 
technischen Einschränkungen betrafen vor allem den Aspekt, dass Plasmodien unter 
einer gewissen Nachweisgrenze nicht detektiert werden können. Die biologischen 
Eigenschaften von Plasmodium falciparum, welche die Genotypisierung erschweren, 
betreffen zum einen die falsche Klassifizierung eines Probenpaares als Rekrudeszenz, 
wenn am Tag der Wiedererkrankung Gametozyten im Blut vorhanden sind. Zum 
anderen sequestriert P. falciparum in Gewebe und ist somit nicht immer im Blut 
nachweisbar. Dies kann dazu führen, dass einzelne Genotypen am Tag 0 zwar bereits im 
Körper des Patienten vorhanden, jedoch durch die Sequestrierung nicht nachweisbar 
sind. Ein weiterer Aspekt ist die falsche Klassifizierung eines Probenpaares als 
Rekrudeszenz, wenn durch Zufall die Wiedererkrankung durch den gleichen Genotyp 
von P. falciparum hervorgerufen wird. Zum Schluss habe ich meine Ergebnisse mit 
publizierten und bereitgestellten Daten verglichen. Es hat sich dabei herausgestellt, dass 
diese in vielerlei Hinsicht miteinander konsistent waren: sowohl meine Ergebnisse als 
auch die Vergleiche zeigten, dass 3D7 einen höheren Polymorphismus aufzeigt und 
dass in jeder Population gewisse Genotypen überrepräsentiert sind, die besonders häufig 
der D10-Familie angehören. 
Die Ergebnisse dieser Studie zeigen, dass die Genotypisierung für Proben von 
Parasitenisolaten aus Burkina Faso erfolgreich eingerichtet werden konnte. Die hohen 
Rekrudeszenzraten, die in dieser Studie gefunden wurden, sind auf Grund der geringen 
Fallzahl nicht statistisch aussagekräftig. Um eine Aussage über die Effizienz der 
Medikamente zu treffen, sollten die Gesamtergebnisse der WANECAM-Studie 
abgewartet werden. Die potenzielle Dominanz von bestimmten, lokal vermehrt 
vorkommenden Parasiten-Genotypen sollte weiterhin kontinuierlich überprüft werden, 
um eine Fehlinterpretation von Malariastudien durch systematische Fehler bei der 
Genotypisierung zu verhindern. 
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Appendix 
7.1 Extended study design 
Inclusion criteria 
To be included in the study, patients had to be above a certain age and weight according 
to the treatment arm. Patients necessarily had to present with fever above 37.5 °C or 
history of fever in the last 24 hours and positive microscopy of Plasmodium sp. with a 
density less than 200 000 / µl. Patients had to be able to swallow oral medication and 
could only be included, if the anamnesis showed no treated malaria episodes in the last 
two weeks. A written informed consent had to be signed and the patient had to be able 
and willing to participate for the follow-up visits. 
Non inclusion criteria 
Patients enrolled in the study could not meet any signs or symptoms of severe malaria 
requiring parenteral treatment. No severe vomiting, no history or evidence of 
cardiovascular, respiratory, hepatic, renal, gastrointestinal, immunological, 
neurological, endocrine, psychiatric disorders, jaundice, infections, malignancy, 
convulsions or other abnormalities. The hemoglobin level had to be > 7 g / dl, ALT 
levels and creatinine levels had to be under a certain range. Women with childbearing 
potential must not be pregnant or planning on becoming pregnant nor lactating. Patients 
with knowledge of positive HIV antibodies, HAV-IgM, HBsAg or HCV antibodies 
were not included in the study. Patients known or suspected to abuse alcohol were not 
included as little as patients who had had treatment with any antimalarial agent in the 
past two weeks prior to inclusion or any investigational drug within 4 weeks prior to 
inclusion. 
Diagnostics of P. falciparum malaria  
To diagnose a malaria infection, two separate Giemsa stained thick and thin films were 
examined. The slides were examined with a binocular microscope and an oil immersion 
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lens. Thick films were analysed to whether the sample contained Plasmodium sp. or not. 
If no Plasmodium sp. was observed in 100 fields the slide was declared negative.  
If the thick film was positive for Plasmodium sp., asexual forms were counted against 
leukocytes based on the formula shown below:  𝑃𝑎𝑟𝑎𝑠𝑖𝑡𝑒 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 𝑝𝑒𝑟 µ𝑙 = 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑃𝑙𝑎𝑠𝑚𝑜𝑑𝑖𝑢𝑚 𝑝𝑎𝑟𝑎𝑠𝑖𝑡𝑒𝑠 × 𝑎𝑐𝑡𝑢𝑎𝑙 𝑙𝑒𝑢𝑘𝑜𝑐𝑦𝑡𝑒𝑠𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑙𝑒𝑢𝑘𝑜𝑐𝑦𝑡𝑒𝑠 𝑐𝑜𝑢𝑛𝑡𝑒𝑑 (200)  
If the parasite count was below 10, the count was increased to 500 leukocytes and if 
gametocytes were seen, a gametocyte count was performed against 1000 leukocytes. 
Drug administration  
If an uncomplicated malaria infection was confirmed microscopically, the randomly 
attributed study drug was administered at the health center under supervision of a study 
team member. Therefore, AL was applied orally twice a day and DP and PA were given 
orally once a day for three consecutive days on day 0, day 1 and day 2 after inclusion.  
Artemether-lumefantrine 
AL was administered twice daily for three days. Water and food was given at the same 
time, as AL is absorbed better in the presence of fats. The dosage of the tablet was of 
20:120 mg. AL was given as Coartem® by Novartis Pharmaceutical Company.  
Table 19: Dosage artemether lumefantrine 
Body weight No. of tablets 
5 to < 15 kg 1 (dispersible) 
15 to < 25 kg 2 (dispersible) 
25 to < 35 kg 3 
≥ 35 kg 4 
 
Dihydroartemisinin-piperaquine 
DP was given once daily for three days. It was taken with water and without food. The 
tablets were given no less than 3 hours after the last meal and patients remained without 
food for 3 hours after drug administration.  
DP was given as Eurartesim® by Sigma-Tau Pharma. 
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Table 20: Dosage dihydroartemisinin-piperaquine 
Body weight  Dose of tablet Amount of tablets 
5 to < 7 kg 20:160 mg ½  
7 to < 13 kg 20:160 mg 1 
13 to < 24 kg 40:320 mg 1 
24 to < 36 kg 40:320 mg 2 
36 to < 75 kg 40:320 mg 3 
75 to 100 kg 40:320 mg 4 
 
Pyronaridine-artesunate 
PA was administered once a day for three days depending on the patient’s body weight: 
from 5 – 20 kg body weight in sachets with a dosage of (pyronaridine:artesunate) of 
(60:20 mg), and above 20 kg body weight in tablets with a dosage of (P:A) of 
(180:60mg). Phase II and Phase III studies on healthy patients and patients with malaria 
had show efficiency and safety at a dose-level range of 7.5:2.5 mg / kg to 15:5 mg / kg 
PA. To secure the safety of PA, a Data Safety and Monitoring Board (DSMB) evaluated 
data from the first 20 and 40 patients after the second treatment course with PA.  
PA was given as Pyramax® by Shin Poong Pharmaceutical. 
Table 21: Dosage pyronaridine-artesunate 
Body weight No. of sachets Body weight No. of tablets 
5 to < 8 kg 1 20 to < 24 kg 1 
8 to < 15 kg 2 24 to < 45 kg 2 
15 to < 20 kg 3 45 to < 65 kg 3 
  65 to < 90 kg 4 
 
Ethical approval 
The Investigator Brochure, the Product Monographs, the signed protocol and the Final 
Informed Consent Form were submitted to the local Ethics Committee (EC). The final 
version of the informed consent form was approved by the local EC. Final approval by 
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the EC and the relevant national Regulatory Authority were provided to the Sponsor 
before the first patient was enrolled in the study.  
The investigators or sponsors submitted progress reports to the EC according to local 
regulations and guidelines. The study was conducted in compliance with the study 
protocol. The informed consent was obtained according to the ethical principles stated 
in the Declaration of Helsinki 2000 version, the applicable guidelines for ICH GCP and 
the applicable local laws and regulations.  
The information about the WANECAM-trial is not complete. The fundamental 
information for the present study was given, but further details were not amplified in the 
thesis at hand. 
7.2 Tables  
Table 22: Number of different genotypes in Bobo-Dioulasso, Kilifi-1 and Kilifi-2 
Allelic type Genotypes 
Bobo-Dioulasso 
Genotypes Kilifi-1 Genotypes Kilifi-2 
3D7 & D10 44  172 74 
3D7 30 97 42 
D10 14 75 32 
 
Table 23: Comparing allele frequencies of genotypes in Bobo-Dioulasso, Kilifi-1 and Kilifi-2 of 
genotypes that occurred > 3 % 
Bobo-Dioulasso Kilifi-1 Kilifi-2 
D10 336 bp excluded D10 371 bp 6.53 % 3D7 272 bp 6.04 % 
D10 417 bp 13.08 % D10 336 bp 5.33 % D10 264 bp 5.03 % 
D10 371 bp 11.22 % D10 261 bp 4.13 % D10 336 bp 4.36 % 
3D7 272 bp 5.61 % D10 298 bp 3.59 % D10 371 bp 4.36 % 
3D7 281 bp 4.67 %  D10 298 bp 3.69 % 
3D7 242 bp 3.74 %  D10 354 bp 3.69 % 
3D7 254 bp excluded  D10 407 bp 3.69 % 
3D7 264 bp 3.74 %   
3D7 276 bp 3.74 %   
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D10 407 bp 3.74 % 
 
Table 24: Genotypes responsible for recrudescences in Kilifi-1: comparing the allele 
frequencies of these genotypes in the baseline population and in recrudescences 
Genotype (bp) Allele frequency Kilifi-1 
population (%) 
Allele frequency Kilifi-1 
recrudescences (%) 
D10: 371 6.53 18.92 
D10: 336 5.33 13.51 
D10: 261 4.13 10.81 
D10: 298 3.59 8.11 
D10: 455 2.72 5.41 
D10: 264 1.85 5.41 
3D7: 251 0.87 2.70 
3D7: 272 1.74 2.70 
3D7: 281 1.31 2.70 
3D7: 297 1.09 2.70 
3D7: 300 0.65 2.70 
3D7: 318 0.87 2.70 
3D7: 340 1.63 2.70 
3D7: 372 0.76 2.70 
3D7: 393 0.87 2.70 
D10: 345 1.41 2.70 
D10: 360 1.85 2.70 
D10: 363 0.33 2.70 
D10: 386 0.65 2.70 
D10: 407 1.09 2.70 
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Table 25: Genotypes responsible for recrudescences in Kilifi-2: comparing the allele 
frequencies of these genotypes in the baseline population and in recrudescences 
Genotype (bp) Allele frequency Kilifi-2 
population (%) 
Allele frequency Kilfi-2 
recrudescences (%) 
D10: 264 5.03 25.00 
D10: 316 1.01 8.33 
D10: 354 3.69 8.33 
D10: 359 2.01 8.33 
D10: 371 4.36 8.33 
D10: 389 2.01 8.33 
D10: 424 1.01 8.33 
D10: 455 2.68 8.33 
3D7: 276 1.68 8.33 
3D7: 281 2.68 8.33 
 
7.3 Figures 
In the following electropherogram and pie charts, 3D7-type alleles are represented in 
green colour, whereas D10-type alleles are depicted in blue colour. 
 
Figure 34: Stutter peaks. X-axis shows length of detected PCR-fragments in bp. Y-axis depicts 
detected intensity in rfu. 
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Figure 35: Allele frequencies Kilifi-1. Frequencies > 5 % are indicated with exact allele 
frequency, with fragment length and allelic type. The green colour depicts 3D7-type alleles and 
the blue colour represents D10-type alleles. Lengths of fragment are indicated as bp. 
 
Figure 36: Allele frequencies Kilifi-2. Frequencies > 5 % are indicated with exact allele 
frequency, with fragment length and allelic type. The green colour depicts 3D7-type alleles and 
the blue colour represents D10-type alleles. Lengths of fragment are indicated as bp. 
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Figure 37: Allele frequencies of recrudescences in Kilifi-1. The genotypes are depicted in their 
respective frequencies and fragment length. The green colour depicts 3D7-type alleles and the 
blue colour represents D10-type alleles. Lengths of fragment are indicated as bp. 
 
Figure 38: Allele frequencies of recrudescences in Kilifi-2. The genotypes are depicted in their 
respective frequencies and fragment length. The green colour depicts 3D7-type alleles and the 
blue colour represents D10-type alleles. Lengths of fragment are indicated as bp. 
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